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Abstract for Thesis Portfolio  
Many people with diabetes find it difficult to adhere to their insulin 
medication regime, and may omit or restrict their insulin doses. Insulin omission has 
been linked to poorer health outcomes.  The reasons behind insulin omission 
however, are not well understood.  
The current research was designed to explore insulin omission in adults with 
type 1 diabetes. The research aims included: 1) To critically evaluate the way that 
adherence to insulin medication had been measured in previous studies. 2) To 
develop an appropriate measure of insulin omission for use in this study. 3) To 
investigate the relationships between insulin omission, general self-efficacy, diabetes 
specific self-efficacy, depression, and diabetes self-management. 4) To investigate 
reasons for insulin omission.  
A systematic review of measures used to assess insulin adherence for people 
with type 1 diabetes was conducted. This demonstrated that existing measurement of 
insulin adherence was inconsistent, measures were not validated for type 1 diabetes, 
and did not allow scope for understanding reasons for insulin non-adherence or 
omission.  
The empirical study included the development of a measure of insulin 
omission as well as an online survey (n=231) assessing factors associated with, and 
reasons for, insulin omission. Results of this study showed that insulin omission was 
associated with low self-efficacy, high depression scores, and poor overall diabetes 
self-management (all p<.001). The narrative information about reasons for insulin 
omission collected in the questionnaire generated themes on: a) Prioritising: 
Forgetting and the demands of daily lifestyle, b) Diabetes-related emotional distress, 
  8
c) Weight control, d) Avoidance: Fear of physical effects, and e) Adaptive responses 
to managing blood sugar levels. 
Theoretical and clinical implications are identified and recommendations for 
further research are discussed. 
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Introduction to the Thesis Portfolio 
The thesis portfolio consists of two main papers: a systematic review and an 
empirical paper, on the topic of insulin adherence and insulin omission in an adult 
type 1 diabetes population. There is a bridging chapter which contains further 
information linking these two papers. Additional methodology and results chapters 
report further information from the empirical study. A final discussion chapter 
integrates the findings from the systematic review and the empirical study and 
discusses these in the context of current literature   
The research within this portfolio focuses on type 1 diabetes. Type 1 diabetes 
is a chronic and complex condition characterised by high blood sugar levels (known 
as hyperglycemia, meaning that an excessive amount of glucose circulates in the 
blood plasma). This has been defined by the World Health Organisation as blood 
glucose levels greater than 7.0 mmol/L when fasting, and greater than 11.0 mmol/L 
two hours after meals. The long-term complications of persistent hyperglycemia can 
result in significant health conditions. Substantial lifestyle adaptations are necessary 
in order to manage the condition effectively, including the monitoring of physical 
exercise and activity, monitoring of blood sugar levels, nutritional management, and 
the use of insulin medication which can be taken by injection or pump.  
Research suggests that many people with diabetes find it difficult to adhere 
closely to their recommended insulin regime, as well as to other aspects of managing 
their diabetes such as exercise and diet. Poorer insulin adherence has been associated 
with increased blood glucose levels. Given the severity of the complications 
associated with chronic hyperglycemia, adherence to insulin medication is critical 
for this population.  Improving adherence is therefore a priority, however there is 
inconsistency in the way that insulin adherence is defined and measured.  
  11
The systematic review aims to investigate the measurement of insulin 
adherence in this population.  The empirical study seeks to develop a measure of 
insulin omission and use this to investigate relationships between insulin omission, 
general self-efficacy, diabetes specific self-efficacy, depression, and diabetes self-
management. Finally, it aims to explore and understand the reasons reported for 
insulin omission. 
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Abstract 
Background  
Poorer adherence to insulin medication has been linked with an increase in 
complications and mortality rates in people with diabetes. Improving adherence is 
therefore a priority, however there is inconsistency in the way that insulin adherence 
is defined and measured. There is currently no review investigating the measurement 
of insulin adherence with an exclusively type 1 diabetes population.  
 
Purpose 
This paper aims to review and critique methods used to measure medication 
adherence in adults with type 1 diabetes. 
 
Data Sources 
MEDLINE, Academic Search Complete, CINAHL Complete, E-Journals, 
PsychINFO, PsychARTICLES, and EMBASE were systematically searched.  
 
Study Selection 
Fourteen papers published between 1993 and 2016 were reviewed, all of which used 
and described a method for measuring adherence to insulin medication in an adult 
type 1 diabetes population. 
 
Data Extraction 
Information about the methods of assessment used to measure insulin adherence, and 
rates of adherence when reported, were extracted from each paper by the lead author.  
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Data Synthesis 
Studies were separated into categories based on the definition and measurement of 
insulin adherence.   
 
Limitations 
Only articles in the English language were reviewed, and the search was limited to 
published studies that were available on the databases searched.  
 
Conclusions 
Insulin adherence is central to blood glucose control and disease management within 
type 1 diabetes, and yet there is currently no gold-standard for defining or assessing 
adherence. The strengths and limitations of different methods currently used are 
appraised, and recommendations are made for future research.  
 
Introduction 
 
Usually diagnosed before adolescence, and with an estimated UK prevalence in 2015 
of approximately 345,000 people, type 1 diabetes is a chronic and complex condition 
characterised by high blood glucose levels (hyperglycemia) (1,2). The long-term 
complications of persistent hyperglycemia include retinopathy and blindness, 
nephropathy and renal failure, ischemic heart disease, stroke, neuropathy, and foot 
ulceration and amputation (3,4). Significant lifestyle adaptations are therefore 
necessary in order to manage the condition effectively, including the monitoring of 
blood sugar levels and of physical exercise and activity, nutritional management, and 
the use of insulin medication (5,6). The National Institute of Clinical and Health 
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Excellence guidelines (5) recommend that type 1 diabetes be treated with multiple 
daily insulin injections to manage blood sugar levels.  
  
The term ‘adherence’ has been defined by the World Health Organisation (7), as “the 
extent to which a person’s behaviour… corresponds with agreed recommendations 
from a health-care professional” (p.3).  This term is now preferred over ‘compliance’ 
which has been criticised for connoting dependence and blame towards the patient 
(8). For the purposes of the current paper, the term insulin omission, defined as when 
people with diabetes miss out insulin doses (9), and the term insulin restriction, 
defined as when people with diabetes take less insulin than required (10), will be 
included under the umbrella of ‘insulin non-adherence’, as both represent a deviation 
from the recommendations of a health-care professional, and are associated with 
worse health outcomes (10,11). These terms are discussed in more detail in Chapter 
2 – Bridging Chapter. Research suggests as many as half of those with diabetes may 
find it difficult to adhere closely to their recommended insulin regime (9), as well as 
to other aspects of managing their diabetes such as exercise and diet (12), although 
there is limited evidence as to the reasons behind this difficultly to adhere (13). 
Poorer insulin adherence has been associated with increased blood glucose levels 
(14,15). Given the severity of the complications associated with chronic 
hyperglycemia (3,4), adherence to insulin medication is critical for this population.   
 
Much of the existing research into insulin adherence in diabetes has combined the 
results of those with type 1 and type 2 diabetes, which is true of both empirical 
papers investigating insulin adherence (9,13,16), and review studies consolidating 
the literature about medication or insulin adherence and measurement (17,18). There 
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are many ways in which type 1 diabetes differs from type 2 diabetes, for example 
type 2 diabetes is associated with lifestyle choices, typically occurs in those over 40, 
and begins with impaired glucose tolerance that can initially be managed with diet 
and weight loss (19,20). Further, many people with type 2 diabetes are treated with 
oral medication (21) rather than taking insulin. A systematic review of insulin 
adherence demonstrated a bias within research in this area towards people with type 
2 diabetes, with 58 (78%) of studies reviewed by Stolpe et al. (17) conducted 
exclusively with people with type 2 diabetes, compared to only 2 (3%) conducted 
exclusively with people with type 1 diabetes. Other systematic reviews relating to 
medication adherence have focused only on type 2 diabetes (22,23). This has meant 
that any conclusions about medication and insulin adherence in diabetes and its 
measurement have been based predominantly on studies investigating type 2 
diabetes (17,18,22,23).  
 
Existing reviews summarising the literature on medication adherence in diabetes 
have reported a lack of consistency in the way adherence is both defined and 
measured (17,18,22,23). Clifford et al. (18) reviewed the measurement of medication 
adherence (which combined adherence to insulin and adherence to oral medication 
taken by those with type 2 diabetes) in adults and children with type 1 and type 2 
diabetes between 2007 and 2013, and described an extensive range of measures 
used. The measures reported included patient or observer assessment, pill counts, 
medication monitoring systems, mobile phone calls, logbooks, and pharmacy claims 
databases. Stolpe et al. (17) reviewed measures of insulin adherence in adults with 
type 1 and type 2 diabetes between 2000 and 2015, and reported less variation in 
methodology compared to Clifford et al. (18). Stolpe et al. (17) reported that the top 
  17
five most commonly used methodologies all used insulin prescription data from 
pharmacy records, with the sixth most common being a self-report questionnaire. 
The inconsistency in findings between these reviews indicates that further 
investigation is required. Further, in order to direct those with type 1 diabetes to 
appropriate resources, it is important to ascertain data about insulin adherence and 
the measurement of insulin adherence in people with type 1 diabetes. 
 
This paper aims to review and critique existing methodologies for measuring insulin 
adherence in adults with type 1 diabetes. It is expected that, as found in mixed 
population reviews, there will be a lack of consistency in the measurement of insulin 
adherence between different studies.  
 
Method 
Data Sources and Searches  
 
A systematic literature search using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (24) was conducted in order to 
identify published articles that described a method of measuring medication 
adherence in adults with type 1 diabetes. A number of databases were systematically 
searched for relevant articles, including PsycINFO, PsycARTICLES, MEDLINE, 
CINAHL Complete, E-Journals, Academic Search Complete, and EMBASE, on 12th 
December 2016. No historical start date was imposed in order to include any studies 
that may have been missed by previous reviews (17,18). The key words used to 
identify studies included ‘type 1 diabetes’ or ‘t1d’ or ‘diabetes mellitus type 1’ or 
‘juvenile diabetes’, as well as ‘adherence’ or ‘compliance’ or ‘nonadherence’ or 
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‘noncompliance’ or ‘omission’, as well as ‘insulin’ or ‘medication’. The search 
eliminated papers with the terms ‘type 2 diabetes’ or ‘type 2 diabetes mellitus’ or 
‘t2dm’, and ‘paediatrics’ or ‘children’ or ‘child’ or ‘adolescents’ or ‘adolescence’.  
The search was limited to articles published in the English language.  
 
Eligibility Criteria  
 
Eligibility criteria for inclusion in the review consisted of: an adult (18 years plus), 
with a diagnosis of type 1 diabetes, as defined by the study, and a quantifiable 
method to measure adherence to insulin medication described by the paper. Papers 
returned from this search that had mixed populations (child and adult, or mixed 
diabetes) but provided separate analyses for these groups and/or adjusted the 
measures used were included, and all designs were considered providing a form of 
measurement was described. Exclusion criteria included studies of a type 2 diabetes 
population, or studies reporting results for only mixed diabetes populations, or 
paediatric populations, or those reporting only mixed populations. Studies reporting 
adherence measures of mixed treatments or behaviours e.g. diabetes self-care 
generally, without specifically reporting insulin adherence, were excluded, as was 
qualitative research which did not include a quantifiable measurement of adherence.  
 
Study Selection  
 
The initial search returned a total of 612 articles, which were screened for inclusion. 
Stage 1 screening included screening the title and abstract for relevance to the 
research question and against the specified inclusion and exclusion criteria. If 
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articles passed this level of screening, or were ambiguous (e.g. if they did not specify 
the age range or diabetes type in the abstract), they were screened using the full text 
(Stage 2 screening). Finally, papers which were not eliminated at this stage were 
eligible for data extraction. The main reasons for exclusion of papers at all stages 
were that they either included both type 1 and type 2 diabetes or defined diabetes as 
‘diabetes mellitus’, or ‘insulin dependent’. Other common reasons for exclusion 
were that a method of measuring insulin adherence was not described, or that insulin 
adherence was not measured independently of other aspects of diabetes care. Figure 
1 depicts this process. Fourteen articles met all study criteria and were included in 
the review. 
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Figure 1 – PRISMA diagram depicting article selection process. 
Reasons for exclusion of 
articles following stage 2 
screening: 
Child population: 6 
Not T1D (diabetes defined as 
‘insulin dependent’, mixed t1 and 
t2, ‘diabetes mellitus’): 22 
Method of measuring insulin 
adherence not described: 10 
Diabetes care generally rather 
than insulin adherence: 6 
Not a quantitative method: 1 
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Data Extraction and Quality Assessment  
 
Data were extracted by the first author (SA). Information extracted from the articles 
included sample size, method of assessing insulin adherence, and any quantitative 
information about rates of adherence to medication reported by the paper. A quality 
assessment of the selected papers was conducted based on the Understanding Health 
Research tool (25), a method for reviewing the quality of health research tested with 
both patients and medical professionals. Only sections relevant to the methodology 
were applied due to the methodological focus of the current paper. The clarity of the 
description of the method for assessing insulin adherence was rated separately in 
order to determine whether the methodology could be replicated based on the 
information given. Ratings of this were from 1 (limited description) to 3 (clearly 
described), see supplementary tables 1 and 2 for full details.  
 
Data Synthesis and Analysis  
 
The outcome of interest was the method used to assess insulin adherence. Methods 
are described together based on similarities in how they defined adherence, and are 
described qualitatively due to the focus on methodology and the heterogeneous 
nature of the studies (26).  
 
Results 
 
Fourteen studies were included in the systematic review, totaling 12,120 participants. 
Of these, ten measured insulin adherence using patient self-report (including 
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interview and questionnaire methods), three used medical databases which were 
based on clinical notes, and one used medical monitoring. Adherence rates reported 
ranged from 10% (27) to 99% (28), although the variety in methods made it difficult 
to usefully compare adherence levels across studies. Eleven of the studies were 
carried out in developed countries, and three (27, 28 & 44), were carried out in 
developing countries. Table 1 lists the included articles and their adherence 
measures, as well as the study design, sample size, rates of adherence reported, and 
quality rating.
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Supplementary Table 1. Quality assessment rating scale 
Category Ethical 
procedures 
mentioned? 
 
Clear 
research 
questions 
or aims? 
 
Information about 
participant 
characteristics? 
 
Paper explains 
how sample is 
representative of 
the wider 
population? 
Sample 
size 
justified?  
Response 
rate / 
withdrawal 
rate 
reported? 
Setting of 
data 
collection 
described? 
 
Method of 
measuring insulin 
adherence clearly 
described? 
 
Overall rating 
Description 
for rating 
Reference to 
study 
approval 
boards or 
bodies, 
and/or 
processes 
such as 
informed 
consent 
Paper 
states what 
it is trying 
to achieve. 
Such as gender, 
age, length of 
illness, type of 
medication, co-
morbidities, etc. 
At least 2.  
Statement about 
how sample 
might be 
generalizable 
(or not) to wider 
population. 
Sample 
size 
discussed 
with 
reference 
to study 
design 
and/or 
statistical 
tests used.  
Is number of 
participants 
who dropped 
out or 
became 
ineligible 
though the 
course of the 
study 
reported? 
Not 
applicable 
for studies 
which were 
one off.  
i.e. using 
databases, 
at clinics, 
in patients’ 
homes, 
online, etc.  
0= no description 
1=very brief 
description 
2=described but 
with some aspects 
of measurement 
e.g. exact wording 
missing 
3=clearly 
described  
 
8-10 Excellent 
6-7 Very good 
4-5 Reasonable 
1-3 Limited 
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Supplementary Table 2. Quality rating of included papers 
 
Authors 
date and 
reference 
Ethical 
procedures 
mentioned? 
 
Clear 
research 
questions 
or aims? 
 
Information about 
participant 
characteristics? 
 
Paper explains 
how sample is 
representative of 
the wider 
population?  
 
Sample 
size 
justified?  
Response 
rate / 
withdrawal 
rate 
reported? 
 
Setting of data 
collection 
described? 
 
Method of 
measuring 
insulin 
adherence 
clearly 
described? 
Overall rating 
(sum of 
individual 
ratings) 
Farsaei et al. 
(2014) 
(28) 
1 1 1 1 0 0 1 3 8 = Excellent 
Trief et al., 
(2014) 
(31) 
1 1 1 1 1 0 1 3 10 = Excellent 
Gomes, & 
Negrato, 
(2016) 
(27) 
1 1 1 1 1 0 1 3 9 = Excellent 
Merwin et 
al., (2014) 
(38) 
1 1 1 0  1 0 1 3 8 = Excellent 
Markowitz, 
Carper, 
Gonzalez, 
Delahanty, 
& Safren, 
(2012) 
(39)  
1 1 1 1 1 1 0 2 8 = Excellent 
Louch, 
Dalkin, 
Bodansky, 
& Conner, 
(2013) 
(33)  
1 1 1 1 0 1 1 2 8 = Excellent 
  25
Merwin et al 
(2015).  
(34) 
1 1 1 1 0 1 1 3 9 = Excellent 
Gurkova, & 
Ziakova, 
(2014). 
(35) 
0 1 1 0 0 1 1 2 6 = Very good 
Peveler, 
Davies, 
Mayou, 
Fairburn, & 
Mann, 
(1993). 
(36)  
1 1 1 1 0 1 1 2 8 = Excellent 
Takii et al 
(2008)  
0 1 1 0 0 0 1 2 5 = Reasonable 
Currie et al 
(2013) 
(41) 
0 1 1 1 0 0 1 1 5 = Reasonable 
Thompson, 
Cummings 
& Chalmers 
(1995) 
(42) 
0 1 1 0 0 - 1 1 4 = Reasonable 
Smith et al 
(1999) 
1 1 1 0 0 - 1 1 5 = Reasonable 
Vimalavathi
ni, Agarwal, 
& Gitanjali, 
(2008). 
(44)  
1 1 1 1 0 0 1 3 8 = Excellent 
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Table 1. Summary table of the assessment of insulin adherence used in articles reviewed 
 
Authors 
and date 
 
N Type of study Method(s) 
used 
Description How insulin adherence was 
defined 
Adherence to insulin rate 
(if reported) 
Clinical 
indicator 
Quality 
Rating 
(Overall 
score for 
methodology, 
and rating for 
clarity of 
description of 
measurement) 
Farsaei et 
al. (2014)  
(28) 
507 Cross- 
sectional 
telephone 
study 
Self-report 
questionnaire 
administered 
by telephone 
Adherence to insulin was 
measured using the 8 item 
Morisky Medication Adherence 
Scale (MMAS), and also using 
the auto-compliance method, 
where patients were asked 
“How many times did you skip 
an insulin injection in the last 
month?’. This was divided by 
the total number of prescribed 
injections and multiplied by 100 
to give a total score.  
On the MMAS a patient was 
considered low adherent if 
they received scores of less 
than 6. Using the auto-
compliance method, patients 
who reported taking more 
than 80% of their prescribed 
insulin dose were 
considered to be adherent to 
insulin.  
Using the MMAS, 22% 
had high adherence, 63% 
had medium adherence 
and 14% had low 
adherence.  
Using the auto-
compliance method 99% 
were adherent.  
None Overall: 
Excellent. 
Clearly 
described. 
 
Trief et al. 
(2014)  
(31) 
6172 Cross-
sectional 
online 
questionnaire 
study also 
using medical 
chart review. 
Group 
comparison 
study.  
Self-report 
questionnaire 
administered 
online. 
Participants were asked ‘How 
often do you miss an insulin 
dose?’ Other areas relevant to 
insulin adherence were also 
reported including 
‘demonstrated accurate 
withdrawal of insulin dose’ 
‘proper storage of insulin vials 
in home’ and ‘buy insulin from 
chemist if insulin is 
insufficient’. 
Four categories of 
adherence to insulin doses 
were reported for analyses: 
missing doses almost never, 
less than once a week, 1-2 
times a week, and ≥ 3 times 
a week. 
 
In the depressed group, 
25% missed insulin 
doses ≥ 3 times a week, 
and 43% missed doses 
almost never. In non-
depressed group, 9% 
missed insulin doses ≥ 3 
and 54% missed doses 
almost never. 
 
HbA1c Overall: 
Excellent. 
Clearly 
described. 
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Gomes, & 
Negrato, 
(2016).  
(27) 
1698 Cross-
sectional 
clinic based 
questionnaire 
study.  
Self-report 
questionnaire 
administered 
during clinic 
visit.  
 
Adherence to insulin was based 
on self-reported scales that 
measured medication-taking 
behavior in the last month, 
using questions adapted from 
the 4-item Moriksy Medication 
Adherence scale (11).  
 
Patients were considered 
high adherent if they 
answered no to all 4 
questions. 
They were considered to 
have moderate adherence if 
they answered yes to one or 
two question. Patients were 
rated as having a low level 
of adherence if they 
answered yes to three or 
four questions. 
10% of patients reported 
maximal adherence, 42%  
reported moderate 
adherence, and 48% of 
the patients reported 
minimal adherence to 
insulin. 
HbA1c Overall: 
Excellent. 
Clearly 
described. 
 
Merwin et 
al., (2014)  
(38) 
276 Cross 
sectional 
online 
questionnaire 
study. Eating 
disorder 
focus but 
general 
population 
sample.  
Self-report 
questionnaire 
administered 
online. 
Three items that covered insulin 
management were used from 
the DEPS-R, Markowitz et al., 
(2010), which is a self-report 
measure assessing eating 
disorder behavior and attitudes 
over the past four weeks.   
Scores were combined to 
make a ‘weight related 
insulin mismanagement’ 
continuous variable for use 
in analysis. 
Adherence rate 
specifically to insulin not 
reported.  
HbA1c Overall: 
Excellent. 
Clearly 
described.  
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Markowitz, 
Carper, 
Gonzalez, 
Delahanty, 
& Safren, 
(2012).  
(39) 
9 Pilot 
intervention 
study of 
cognitive 
behavioural 
therapy for 
adherence 
and 
depression. 
Self-report 
questionnaire 
administered 
during 
interview with 
clinician.  
 
Participants were instructed to 
report how often they took their 
insulin on a 10-point scale from 
0% to 100% of the time in the 
past 2 weeks. This 
questionnaire was adapted from 
a questionnaire used by Lu et al 
to assess adherence to 
antiretroviral medications. 
Higher scores were taken as 
increased adherence, and 
scores were used for pre and 
post comparisons.  
Baseline and post 
intervention self-
reported insulin doses 
were 77% and 87% 
respectively.  
HbA1c Overall: 
Excellent. 
Some aspects 
of 
measurement 
missing. 
 
Louch, 
Dalkin, 
Bodansky, 
& Conner, 
(2013). 
(33) 
18 Randomised 
controlled 
trial of text 
messaging 
intervention. 
Self-report 
question about 
frequency of 
injections. 
Participants self-reported how 
many insulin injections they 
self-administered in the 
morning, afternoon and evening 
of the previous week. 
Increased injections were 
taken as increased 
adherence. 
Only mean differences 
pre and post intervention 
reported, not rates.  
None Overall: 
Excellent. 
Some aspects 
of 
measurement 
missing. 
 
Merwin et 
al (2015).  
(34) 
83 Ecological 
momentary 
assessment – 
telephone 
questionnaire 
study. Eating 
disorder 
focus and 
sample.    
Self-report 
repeated 
single 
question 
administered 
by automated 
telephone 
programme. 
  
Participants were asked over the 
phone after eating, “Did you 
take enough insulin to cover 
your food?” They could press 
keys indicating “yes,” “maybe,” 
or “no.” Participants were 
instructed to respond “no” if 
they intentionally took less 
insulin than was needed (under 
dosed) or completely omitted a 
necessary insulin dose.  
 
Insulin restriction at each 
eating occasion was defined 
as responding “no” to the 
question: “Did you take 
enough insulin to cover your 
food?” 
Participants reported 
restricting insulin for 
22% of the eating 
episodes recorded. 
HbA1c Overall: 
Excellent. 
Clearly 
described.  
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Takii, et 
al., (2008) 
(11)  
109 Interview 
study with 
eating 
disorder 
focus and 
sample.  
Self-report 
clinical 
interview and 
clinician 
report medical 
records.  
Patient interview done in a 
counselling session. 
Information crosschecked using 
patient history and the HbA1c 
course reported by the referring 
physician.  
Insulin omission was 
defined as 
omission/reduction of at 
least one-quarter of the 
prescribed insulin when 
done mainly for preventing 
weight gain. 
68% of type 1 diabetic 
females with clinical 
eating disorders 
presented with severe 
insulin omission.  
HbA1c Overall: 
Reasonable. 
Some aspects 
of 
measurement 
missing.  
Gurkova, 
& Ziakova, 
(2014) 
(35) 
 62 Cross-
sectional 
structured 
interview 
with 
questionnaire
s 
Structured 
interview and 
questionnaire 
Patient interview used to collect 
information about self-
adaptation of insulin dosage. 
Information was also collected 
during clinic visits.  
 
Not labelled as adherence, 
but whether insulin was 
adapted in relation to other 
factors such as carbohydrate 
intake, glycaemia values or 
degree of physical activity 
was measured.  
48/62 reported self-
adaptation of insulin 
dose in response to 
results of self-monitoring 
of glucose levels, sick 
days, exercise, 
carbohydrate intake. 
  
History 
of hypo-
glycaemi
a.  
Overall: Very 
good. 
Some aspects 
of 
measurement 
missing. 
 
Peveler, 
Davies, 
Mayou, 
Fairburn, & 
Mann, 
(1993) 
(36)  
113 Cross-
sectional 
interview 
study with 
questionnaire
s 
Semi 
structured 
interview, 
self-report 
questionnaire, 
and medical 
monitoring.  
 
 
Subjects were questioned in 
detail about insulin injections, 
including questions about 
taking injections regularly, and 
adjusting injections in response 
to test results.  
Not labelled as adherence, 
but whether injections were 
taken regularly was 
measured, as was whether 
patients had attempted to 
adjust their insulin dose as a 
response to blood glucose 
test results to improve their 
blood glucose control.  
98% reported taking 
their injections regularly, 
and adjusting their 
insulin dose in response 
to the test results at least 
occasionally. 60% had 
attempted to adjust their 
insulin dose in the light 
of test results in last 
month.  
HbA1c Overall: 
Excellent. 
Clearly 
described.  
 
  30
Currie et al. 
(2013) 
(41)  
2946 Three-year 
retrospective 
case-note 
review 
Clinician 
report -
database 
records 
Case-note review following up 
patients over time to assess 
outcomes. Patients had been 
given a diagnosis of non-
compliance with medication at 
a clinical appointment during an 
initial 30-month observation 
period, which was recorded in 
their notes. How this decision 
was made was not described by 
the paper.  
 
Patients were classified as 
medication non-compliant if 
this was recorded as a 
diagnosis in their medical 
notes. 
2% were classified as 
medication non-
compliant in the 30-
month compliance 
assessment period.  
 
None Overall: 
Reasonable. 
Limited 
description  
 
Thomspon 
et al. 
(1995) 
(42) 
122 Three-year 
retrospective 
case-note 
review 
Clinician 
report - 
database 
records 
Case-note review of patients 
who were admitted for 
ketoacidosis.  
Insulin error or 
manipulation defined if 
notes in medical records 
documented that 
ketoacidosis had developed 
due to abnormal insulin 
treatment behaviour 
following an interview by 
diabetes team. How this was 
decided is not recorded by 
the paper.  
 
 
 
 
 
 
 
 
 
 
 
Insulin error or 
manipulation was 
reported for 42% of 
young adults (under 25) 
and 11% of older adults 
(over 25) 
None Overall: 
Reasonable. 
Limited 
description.  
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Smith et al. 
(2009) 
(43) 
31 Clinical audit  
group 
comparison 
study. Case-
note review  
Clinician 
report -
database 
records  
Case-note review – review of 
notes over 4 clinical visits 
where changes to insulin regime 
were discussed. The proportion 
of agreed changes to insulin 
regimen adhered to across visits 
one to four was calculated for 
each set of consecutive visits 
(one to two, two to three, and 
three to four). Patients scoring 
≥50% were defined as adherent. 
Adherence scores of the percent 
of advice taken were also 
measured. 
 
Adhering to more changes 
to insulin regime between 
visits, and following a 
greater percentage of advice 
was taken as being more 
adherent.  
Of those with hypo-
glycaemia unawareness 
54% were defined as 
adherent and they 
followed on average 
19% advice, compared to 
those with awareness of 
hypo-glycaemia of 
whom 87% were defined 
as adherent and they 
followed 28% advice. 
None Overall: 
Reasonable. 
Limited 
description.  
Vimalavath
ini, 
Agarwal, & 
Gitanjali, 
(2008) 
(44)  
67 Intervention 
study of 
psycho-
education for 
knowledge/ 
adherence.  
Medication 
monitoring 
 
Patients had their blood plasma 
levels medically tested.  
 
Adherence to insulin was 
defined as plasma insulin 
levels of at least 50% of 
their previous insulin dose. 
Adherence increased 
from 82% to 86% 
following intervention.  
Blood 
glucose, 
HbA1c, 
and 
plasma 
insulin.  
Overall: 
Excellent. 
Clearly 
described. 
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Patient Self-report 
 
 
Morisky Medication Adherence Scale 
Two studies (27,28) used the Morisky Medication Adherence Scale (29), a 
previously validated scale for measuring adherence to medication which asks 
participants to respond to questions such as ‘Do you ever forget to take your 
medication?’ and ‘Are you careless at times about taking your medication?’ (p.69). 
Gomes and Negrato (27) used this four-item version (29), and adapted the questions 
from the original questionnaire to focus on insulin rather than medication in general, 
also changing the language of the questionnaire, for example ‘careless’ was 
exchanged for ‘negligent’. A strength of this measure is that it is specific to diabetes, 
and therefore may be relevant for this population. Farsaei et al. (28) used an eight-
item version previously validated with people with type 2 diabetes in Thailand (30). 
However, Sakthong et al. (30) concluded that the 8-item measure had poor 
sensitivity in their type 2 diabetes population, and therefore may have failed to 
identify some people who were non-adherent. Both versions had a cut off score to 
define adherence and non-adherence. Neither version of this questionnaire has been 
validated in people with type 1 diabetes to the authors’ knowledge.  Both studies 
using this scale have a quality rating of ‘excellent’ in terms of their methodology as 
reviewed by the current study, and the description of the assessment of insulin is 
clear in both cases and so could be replicated in further research.  
 
Single question about frequency of missing insulin doses 
Five self-report studies used for measurement a frequency measure for taking or 
missing insulin doses (28,31-34), such as “how often do you miss an insulin dose? 
(31)” and “did you take enough insulin to cover your food” (34). This method 
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provided a means of measuring change by allowing for a direct comparison over 
time following an intervention. However, it did not necessarily take into account the 
prescribed dose of insulin medication, or account for those who may be taking more 
insulin than they need. The methodologies for these studies were rated as excellent 
by the current paper, although two (32,33) did not report the precise wording of the 
measure used, making replication of their method more difficult. Additionally, these 
methods, while useful for quantifying adherence, do not provide any explanation 
about the reasons for adherence or non-adherence. None of these questions, to the 
authors’ knowledge, had been validated for use in type 1 diabetes.  
 
Clinical Interview about Adapting Insulin Dose 
Two papers measured the extent to which insulin was adapted or adjusted in light of 
food, blood sugar readings, or physical activity (35,36). Both studies used cross 
sectional clinical interviews as well as questionnaires, which can provide a depth of 
understanding and quantitative data can also be collected and used for measurement. 
Peveler et al. (36) also used medical data alongside this which may have provided 
further information with which to interpret the responses of participants. This can be 
useful given that there is often some discrepancy between medical data and patient 
report (37). Both studies were clearly described and had very good and excellent 
methodologies as rated by the assessment tool.  
 
Eating Disorders Research 
Three of the self-report studies measured adherence to insulin only if associated with 
eating disorders, weight or food (34,38,39) Merwin et al, (38) used three items from 
the 16 item Diabetes Eating Problems-Revised (39), a self-report measure assessing 
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eating disorder behaviour and attitudes, creating a ‘weight related insulin 
mismanagement’ variable which was used to investigate associations with other 
variables. Takki et al. (11) measured, recorded, and quantified missed insulin doses 
only when they were missed primarily for the purpose of preventing weight gain. 
Merwin et al. (34) sampled participants with eating disorder symptomology, and 
used an automated telephone system asking them to respond to a question about 
whether they had taken enough insulin to cover their food, and recorded the 
frequency of these responses. These studies were included as they measured an 
aspect of adherence to insulin medication, and weight concerns have been strongly 
linked to insulin adherence in the literature (e.g.10,40), making measurement of this 
occurrence both important and helpful. However, it can be argued that by only 
focusing on weight related insulin mismanagement this may obscure other reasons 
for non-adherence, and therefore not offer a robust measure of insulin adherence 
more generally.  
 
Case-note Review  
 
Three of the papers identified (41-43) used this method and defined adherence based 
on historical patient case notes written by a clinician. This method of measuring 
insulin adherence allows the researchers to relatively quickly examine data from 
many patients, which may increase the generalisability of the findings. However, in 
all three of these studies, the way in which clinicians made a decision about 
adherence, and whether this was consistent between clinicians, was not reported. As 
a result, these studies scored more poorly for the description of the measurement of 
adherence, as although the method of coding the notes could be replicated based on 
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the descriptions, it was not possible to tell on what basis, or with what consistency, 
the original decision had been made. The quality of the methodologies overall was 
rated as reasonable.  
 
Medical Monitoring  
 
Vimalavathini, Agarwal, & Gitanjali, (44) used plasma insulin levels, and defined 
adherence to insulin as those patients with plasma insulin levels of at least 50% of 
their previous insulin dose. This method of measuring adherence controls for 
reporting bias such as under/over reporting by participants, and can provide an 
objective and measurable description of adherence. However, it also restricts the 
measurement to only the latest dose of insulin, and so cannot be used as a general 
measure of a person’s adherence over time unless multiple samples are collected, as 
well as being labour intensive and costly (45). This methodology was clearly 
described, and rated as excellent by the assessment tool.  
 
Discussion 
 
This review identified studies reporting methods of assessing adherence to insulin 
medication in people with type 1 diabetes. It was identified that there were multiple 
definitions of insulin adherence and varying methodologies to measure this between 
the 14 included studies. A range of rates of adherence to insulin were also reported 
(10-99%, 27,28). This range of results is consistent with findings in a type 2 diabetes 
or mixed diabetes population (18,22,23,46). Compounding the problem of variation 
is the lack of clarity in the field about what constitutes ‘good’ insulin adherence. In a 
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review of medication adherence measures in type 2 diabetes (23), the authors 
comment on the ‘urgent’ need to develop consensus about what constitutes good 
adherence, as well as the need for consistency of measures and cut off points. The 
lack of consistency makes studies aimed at increasing adherence difficult to 
compare, and the current review illuminates a similar problem with measurement in 
type 1 diabetes. 
 
The finding of self-report being the most common method of assessing adherence is 
supported by Clifford et al. (18), who find that all 14 studies carried out in a type 1 
diabetes population included in their review use some form of self-report. Patient 
self-report is sometimes regarded as a somewhat unreliable source of information, as 
it is thought that patients may over-report their adherence (47). While this is the case 
in some studies, a review by Garber et al. (37) found that questionnaire and diary 
methods had moderate to high concordance with other measures sometimes used to 
assess medication adherence including drug levels, pill count, claims data, and 
clinical opinion. However, none of the questionnaires or single questions reviewed in 
the current study were empirically validated for use as a stand-alone measure of 
insulin adherence in a type 1 diabetes population to the knowledge of the authors.  
The questionnaire measures reviewed did not allow participants to record or explain 
their reasons for adherence or non-adherence, and it can be argued that collecting 
this information along with rates of adherence may be critical when considering 
interventions designed to improve adherence. Fairman (45) recommends that 
questionnaire items should be carefully constructed in order to “avoid the 
implication that non-compliant patients are in some way derelict” (p.500). It is 
feasible in the opinion of the authors of the current study that wording such as 
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‘negligent’ or ‘careless’ used in the Morisky Medication Adherence Scale and 
adaptation (27,29) may carry this implication. Clinical interviews, although 
providing a depth of information, may be time consuming for both the clinician and 
the participant (45). Database methods assessing clinical opinion may offer a time 
efficient way to collect adherence data on a large number of participants, but there 
may be issues around reliability and validity, as no depth of information can be 
gathered, and consistency between clinicians is not controlled (or at least, not 
described by the papers). Finally, medical monitoring can provide an objective 
measure of adherence, which controls for under or over reporting by patients. 
However, the method described in this review would require routine testing of 
plasma levels, which may be time consuming for the clinician, and the patient, and 
again does not allow for exploration of why patients may not be adherent with their 
insulin regime.  
 
The current review also highlights the relative inequality in the number of studies on 
insulin adherence conducted in people with type 1 diabetes compared to type 2 
diabetes (22,23). Despite the broader inclusion criteria (not restricted by date or 
study design), only 14 studies could be identified, which is considerably fewer than 
identified by previous reviews of predominantly type 2 diabetes or mixed type 1 and 
type 2 studies (17,18,22,23,46). A more detailed discussion of these results is 
available in Chapter 6 – Discussion.  
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Strengths and Limitations 
 
This paper only reviewed articles available in the English language, and only those 
that were published, as ‘grey literature’ or articles currently in press were not 
actively sought out. One reviewer (SA) conducted the literature search, data 
extraction, and data synthesis, meaning that the potential for studies to be missed and 
the risk of bias was greater than if this had been co-reviewed. The search was limited 
to articles published on the databases searched. Compared to previous systematic 
reviews in this area, a relatively small number of papers met all inclusion criteria. 
Pre-defined eligibility criteria were used, and PRISMA guidelines (13) were 
followed, which contributed to the robustness of the review. 
 
Recommendations 
 
There are advantages and disadvantages of each of the methods described and 
reviewed, which should be considered when assessing whether they can be 
recommended as an appropriate standardised measure of insulin adherence moving 
forwards. The majority of studies used self-report measures, which have the 
advantage of being relatively practical to administer. Questionnaires and diaries in 
particular have been found by Garber (37) to have higher concordance with other 
measures of medication adherence when compared with interview methods. Existing 
self-report measures do not explore the reasons for non-adherence, there is no agreed 
definition of when adherence is achieved, and none of the measures reviewed had 
been validated specifically in a type 1 diabetes population. The conclusions of this 
review support the case for the development and validation of a measure of insulin 
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adherence for type 1 diabetes that incorporates patient involvement to promote 
acceptability, is empirically validated in order to be sure of validity and reliability, is 
time efficient for both clinicians and patients, and allows for recording of reasons for 
non-adherent behaviour, allowing information crucial for interventions promoting 
adherence to be collected. Further, the inequality in the number of studies on insulin 
adherence in type 1 diabetes compared to type 2 diabetes, and the mixing of these 
populations in research highlights a need for more research to be carried out with 
those with type 1 diabetes, to ensure that resources and interventions can be tailored 
appropriately to meet the needs of this population. 
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Bridging Chapter 
Insulin Adherence and Insulin Omission 
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 This chapter aims to provide a bridge between the systematic review and the 
empirical study carried for this project by defining the terms used, and by 
introducing insulin omission. 
2.1 Insulin Adherence 
The current systematic review focuses of the topic of insulin adherence. The 
term ‘adherence’ has been defined by the World Health Organisation, as “the extent 
to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a 
health-care professional” (Sabaté, 2003, p. 3).  Medication adherence in particular 
has been defined as “whether patients take their medication as prescribed (e.g. twice 
daily), as well as whether they continue to take a prescribed medication” (Ho, 
Bryson, & Rumsfeld, 2009 p. 3028). Medication adherence in people with type 1 
diabetes refers to insulin, given that insulin is the medical treatment for people with 
type 1 diabetes recommended by The National Institute of Clinical and Health 
Excellence guidelines (NICE, 2016). This is distinct from medication adherence in 
type 2 diabetes as people with type 2 diabetes may also take medication in oral form, 
such as oral hypoglycemic agents (Inzucci, 2002), and may only need to take insulin 
when the disease has progressed (Taylor, 2013).  As the current systematic review 
describes, previous research has sometimes combined these different types of 
medication adherence along with types of diabetes (e.g. Clifford, Perez-Niever, 
Skalicky, Reaney, & Coyne, 2014). For the purposes of the current research, and in 
reference to type 1 diabetes, ‘insulin adherence’ refers to when insulin is taken as 
prescribed (Stolpe, Kroes, Webb, & Wisniewski, 2016). 
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2.2 Insulin Omission 
2.2.1 Definitions  
The term insulin omission, as noted in the current systematic review, is a 
specific type, or subsection, of insulin adherence. Insulin omission has been defined 
as when “...inadequate insulin is injected for the calories ingested, blood glucose 
may increase markedly. As a consequence, glycosuria occurs and the volume of 
urine produced increases. The end result is the excretion of large amounts of glucose 
(and thus calories) in the urine, resulting in short-term reduction in weight from fluid 
loss and some caloric restriction.” (Crow, Keel, & Kendal., 1998, p. 234). Insulin 
omission can be referred to as the missing of insulin doses completely (Peyrot, 
Rubin, Kruger, & Travis, 2010), while the term insulin restriction has been used 
when individuals choose to take less insulin than they need (Goebel-Fabbri et al., 
2008). Insulin non-adherence may comprise these two behaviours, and can also 
include taking more insulin than would be recommended (overdosing), and/or taking 
the correct amount of insulin but taking it at the wrong time (Brod, Rana, & Barnett, 
2012). Furthermore, insulin non-adherence may incorporate other behaviours that 
make it difficult to adhere fully to the prescribed insulin dose, such as not checking 
blood glucose levels (Miller et al., 2013). As the current systematic review details, 
studies measuring insulin adherence have often chosen one particular category or 
definition of insulin adherence on which to base their measurement, such as insulin 
restriction (Merwin et al., 2015), or adaptation of insulin dose to test results 
(Gurkova & Ziakova, 2014). In the current empirical study insulin omission is 
defined as when insulin doses are missed completely, insulin restriction is defined as 
when doses are reduced, synonymous with under-dosing, and overdosing is defined 
as when more insulin is taken than required.  
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2.2.2 Short-term Effects of Insulin Omission 
Insulin omission has been linked to poorer blood glucose control because 
when insulin is omitted, the body is not able to absorb sugar, resulting in 
hyperglycemia (Randløv & Poulsen, 2008). The short-term consequences of 
hyperglycemia include passing more urine than usual, becoming very thirsty, 
headaches, tiredness, and weight loss (Diabetes UK, 2017a). In severe cases, a lack 
of insulin can result in diabetic ketoacidosis (DKA). This occurs when the body, in 
the absence of glucose, starts to break down other body tissues for energy. 
Chemicals known as ketones are a by-product of this process which, if allowed to 
build up, can be fatal (Diabetes UK, 2017b).  
2.2.3 Long-term Effects of Insulin Omission 
The potential long-term consequences of persistently high blood glucose 
levels include a number of macrovascular and microvascular complications, such as 
blindness, kidney failure, foot ulceration which can lead to amputation, premature 
heart disease, and stroke (NICE, 2016). National guidance for the treatment of type 1 
diabetes (2016) states that the risk of these complications is greatly reduced by the 
appropriate management of blood sugar levels through, in part, adherence to insulin 
medication.  
In an 11-year longitudinal study of 234 women, Goebel-Fabbri et al. (2008) 
identified 71 women and adolescents who reported insulin restriction at baseline. 
They defined this insulin restricting group as women who responded affirmatively to 
the question “I take less insulin than I should”. They reported that at follow up, those 
who had restricted insulin had a three times higher risk of mortality, were more 
likely to have died younger (mean age 45 vs. 58 years), and that they also had higher 
rates of nephropathy (kidney damage) and foot problems.  
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2.2.4 Insulin Omission and Eating Disorders 
As described by Crow et al. (1998), insulin omission results in sugar and 
subsequently also calories being excreted from the body in the urine. This results in a 
temporary weight loss, and insulin omission has most commonly been studied as for 
the purpose of achieving weight loss (e.g. Takki et al., 2008 Peveler et al., 2005; 
Pinhas‐Hamiel et al., 2013). 
 In a study investigating the effects of insulin omission in relation to eating 
disorders, Takii et al. (2008) defined insulin omission as “omission/reduction by 
participants of at least one quarter of the prescribed insulin mainly for the purposes 
of preventing weight gain” (p. 260). In their sample of 109 females with type 1 
diabetes and clinical eating disorders, they found that duration of severe insulin 
omission was the factor most closely associated with retinopathy (eye damage) and 
neuropathy (kidney damage) when compared to the duration of self-induced 
vomiting and duration of binge eating. This indicates that although their sample may 
have had other physical complications associated with eating disorders, insulin 
omission played the largest role in the poor health outcomes of these women.  
Also in relation to eating disorders, Peveler et al. (2005) conducted a 
longitudinal study of women with type 1 diabetes, and measured participants as 
‘misusing’ insulin if they reported intentionally reducing or omitting their insulin 
dose to control their weight. They found that in their sample of women age 20-38 
year (after 8-12 year follow up from baseline), there was strong relationship between 
a history of insulin misuse and hospital admissions for DKA. 
The use of insulin omission as a method of weight control or prevention of 
weight gain may meet the criteria for bulimia nervosa as specified by the diagnostic 
and statistical manual of mental disorders (DSM-V; American Psychiatric 
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Association, 2013), which states, as a criterion for diagnosis, “recurrent 
inappropriate compensatory behaviours in order to prevent weight gain such as… 
misuse of laxatives, diuretics, or other medications” (p. 345).  This association has 
led to the term ‘diabulimia’ being coined, referring to when individuals with diabetes 
omit insulin as a means to control their weight (Ruth-Sahd, Schneider, & Haagen, 
2009).  
While research has found insulin omission for weight control to be a 
consistent finding, other reasons for omission are also implicated. Polonsky et al. 
(1994) found that although just over half of their participants who omitted insulin did 
so as a means of weight control, the remainder did so for other reasons which were 
not investigated (or not reported). Three studies to the knowledge of the author have 
specifically explored potential reasons for insulin omission in addition to weight 
control, (Sullivan, 2012; Peyrot, Barnett, Meneghini, & Schumm-Drager, 2012a; 
Farsaei, Radfar, Heydari, Abbasi, & Qorbani, 2014). Findings from these studies 
suggest that, ‘stress and emotional problems’ (Peyrot et al., 2012a), ‘delaying and 
then forgetting’ (Sullivan, 2012), and ‘embarrassment’ (Farsaei et al., 2014) are also 
important factors in the role of insulin omission.  There is considerable variability in 
the reported findings however, and reasons for insulin omission is an area that the 
current empirical study intends to explore in more detail.  
2.3 Physical Health and Mental Health 
Research has established a consistent link between the incidence of poorer 
physical health and poorer mental health (Naylor et al., 2016). Those with long-term 
physical conditions have been found to be more likely to develop mental health 
difficulties, and those with mental health difficulties have been shown to have a 
higher risk of developing physical health complications or conditions (Scott et al., 
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2009; Robson & Gray, 2007, Stein, Cox, Afifi, Belik, & Sareen, 2006). A recent 
publication by The King’s Fund (Naylor et al., 2016) highlighted the number of 
ways in which mental health and physical health can impact upon each other, 
including the side effects of medication (e.g. steroids, or psycho-tropic medication), 
the psychological impact of living with a chronic condition, and the direct effects of 
stress on the cardiovascular, nervous, and immune systems.  
Diabetes has not been excluded from this trend, and research shows that 
those living with schizoaffective disorder have approximately five times higher rates 
of type 2 diabetes than would be expected in the general population, and that those 
with bipolar disorder have two times higher rates (Regenold, Thapar, Marano, 
Gavimeni, & Kondapavuluru, 2002). Further, a review by Barnard, Skinner, and 
Peveler (2006) revealed that the prevalence of clinical depression in those with type 
1 diabetes was around four time higher than non- depressed control group subjects.  
Of significance, a meta-analysis conducted with studies including type 1 and 
type 2 diabetes demonstrated that those with both diabetes and depression were more 
likely to develop diabetes related complications compared to non-depressed control 
groups with diabetes (De Groot, Anderson, Freedland, Clouse, & Lustman, (2001). 
There are number of possible explanations for the poorer health outcomes in those 
with both diabetes and depression, including poorer diet and functional impairment 
compared to non-depressed people with diabetes (Ciechanowski, Katon, & Russo, 
2000). However,  a previous meta-analysis by Gonzalez et al. (2008) has found that 
depression symptom severity is associated with non-adherence to diabetes regime, 
which indicates that non-adherence may, in part, explain the worse outcomes in 
those with depression and diabetes. Furthermore, depression has been specifically 
linked to insulin omission in those with type 1 diabetes, with Trief et al. (2014), 
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reporting that people with symptoms of depression were more likely to omit insulin. 
Given the established link between insulin adherence, poorer blood glucose control, 
and physical health complications as discussed, the role of mood is an important area 
for research, and will be considered alongside potentially related concepts such as 
self-efficacy in the empirical paper.  
2.4 Insulin Injections and Insulin Pumps 
 While the traditional method of insulin delivery is via injections, and 
measures of insulin adherence and omission are often phrased using the word 
injection (e.g. Louch et al., 2013), more recently insulin pumps have become 
available as an alternative method of administering insulin doses (Diabetes UK, 
2017c). Insulin pumps are a battery operated device that provide the body with 
regular doses of insulin throughout the day. This can be done automatically, 
eliminating the need for injections, although additional doses are able to be 
programmed when needed (for example at meal times depending on carbohydrates 
ingested), and blood sugar levels  still need to be checked to inform decisions about 
additional doses.  Insulin pumps can be purchased by those with diabetes, or are 
available from the NHS in cases where despite good adherence, a person’s blood 
sugar is still not well controlled (Diabetes UK, 2017c). A list of the advantages of 
insulin pumps over injections is available from diabetes.co.uk (2017) in their article 
‘Multiple daily injections vs insulin pumps’, retrieved from 
http://www.diabetes.co.uk/insulin/mdi-vs-insulin-pumps.html. There is evidence that 
being given an insulin pump improves a person’s adherence (Pickup, Mattock, & 
Kerry, 2002).’ 
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Abstract 
Objective 
Many people with type 1 diabetes find it difficult to adhere to their insulin 
medication regime, and may omit or restrict their recommended insulin doses. This 
is associated with an increase in complications and mortality rates. To date no study 
has explored this behaviour in relation to self-efficacy, and research in this area has 
been hindered by the lack of an appropriate measure of insulin omission. The current 
study aimed to investigate the relationship between insulin omission, diabetes self-
management, mood, and self-efficacy, as well as the reasons for omission, using a 
self-report measure of insulin omission developed for the purposes this study. 
 
Research Design and Methods 
This cross-sectional online survey included 231 participants who completed 
questionnaire measures of general self-efficacy, diabetes specific self-efficacy, 
depression, diabetes self-management, and an insulin questionnaire developed for 
this study. The insulin questionnaire was designed to collect both quantitative and 
narrative data which requested participants’ reasons for omitting insulin.  
 
Results  
Group comparisons using either independent t-tests or Mann-Whitney tests revealed 
that insulin omission was associated with lower general self-efficacy, lower diabetes 
specific self-efficacy, higher depression scores, and poorer diabetes self-
management (all p<.001). Thematic analysis of the narrative data revealed a number 
of themes that characterised insulin omission, including a) Prioritising: forgetting 
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and the demands of daily lifestyle, b) Diabetes related emotional distress, c) Weight 
control, d) Avoidance: Fear of physical effects, and e) Adaptive responses to 
managing blood sugar levels. 
 
Conclusions 
This study illuminates the role of self-efficacy and depression in insulin omission in 
relation to both quantitative and narrative findings. 
 
Introduction 
 
Research suggests that many people with diabetes find it difficult to adhere to their 
recommended insulin regime (1,2), which is an essential part of the management of 
type 1 diabetes as recommended by The National Institute of Clinical and Health 
Excellence guidelines (3). Individuals with type 1 diabetes may on occasion choose 
to take less insulin than recommended, or to miss out insulin doses completely (4). 
This behaviour is referred to as ‘insulin restriction’ (5) and ‘insulin omission’ (2) 
respectively. These can be considered to reflect specific areas of adherence (or non- 
adherence), commonly defined as whether patients take their medication as 
prescribed (6), to insulin medication. Adherence to insulin medication is in turn part 
of the broader self-management of diabetes, which also includes monitoring of 
physical exercise and activity, monitoring of blood sugar levels, and nutritional 
management (3,7).  
 
Insulin omission and restriction have been linked to significantly poorer long-term 
physical outcomes (5,8). Polonsky and colleagues found that women who omitted 
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insulin had more diabetes related hospital admissions and higher rates of retinopathy 
and neuropathy compared to those who did not (8). Goebel-Fabbri and colleagues 
found in an 11-year longitudinal study, that women with type 1 diabetes who 
reported insulin restriction were three times more likely to have died, died 
prematurely (mean age 45 vs. 58 years), and present with more complications, 
compared to those who reported not restricting insulin (5).  
 
Despite the harmful consequences of this behaviour, there is a limited understanding 
as to why people do not always take insulin medication as prescribed (9). 
Researchers have more commonly investigated the general self-management of 
diabetes, and as a result self-management has been empirically linked to a number of 
risk factors and psychological constructs. Poorer self-efficacy, defined as ‘an 
individual’s judgment of his or her capabilities to organize and execute a course of 
action’ (10 p.197) has been associated with poorer diabetes self-management in 
different ethnicities and levels of health literacy (11,12). Bandura’s social learning 
theory (13) states that individuals perform activities that they perceive that they can 
cope with and avoid activities which they do not believe that they can cope with. It 
may therefore follow that that low self-efficacy can lead to avoidance, which may 
take the form of insulin omission. However, no study to date has investigated self-
efficacy in relation to insulin omission.  
 
Depression has been linked to poorer diabetes self-management (14,15) and to 
insulin omission specifically in people with type 1 diabetes (16). Trief et al. used 
questionnaires on enrollment to an endocrinology clinic, and reported that 
participants with symptoms of depression were more likely to miss insulin doses 
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(16). However, Peyrot et al. using a web survey found no association between a 
history of depression and reported insulin omission in those with type 1 or type 2 
diabetes combined (2). Additionally, in the three existing studies looking at reasons 
for insulin omission, Sullivan (17), using interview methods, found that participants 
with type 1 diabetes did not report low mood or depression as a reason for or 
explanation of insulin omission, and Farsaei et al. (18) using a telephone survey did 
not report mood as one of the reasons for insulin omission. Peyrot et al. (19), using a 
web survey, did not report any findings relating to depression, but found that ‘stress 
or emotional problems’ was the fourth most common reason selected by participants 
with type 1 or type 2 diabetes to account for insulin omission. These inconsistencies 
in the reporting of and role of depression indicate that further investigation is 
required. As there are known interventions for depression, and for low self-efficacy 
in managing diabetes (20,21), ascertaining the link between these constructs and 
insulin omission may helpfully inform or develop these interventions. 
 
The discrepancy in findings of whether mood may lead to, or be a consequence of, 
insulin omission alludes to a variety of measurement issues associated with the 
assessment of insulin omission. First, the use of samples combining responses from 
those with type 1 and type 2 diabetes has led to a lack of clarity, given evidence that 
differences exist in insulin omission between these groups. Peyrot et al., (2) found 
that those with type 2 diabetes were more likely to omit insulin than those with type 
1 diabetes. In addition, risks factors for the presence of insulin omission in these 
groups were different, with diet non-adherence being more prominent in type 1 
diabetes, and demographic factors such as income, education, and age playing more 
of a significant role in those with type 2 diabetes (2). Second, as described with the 
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role of mood and insulin omission, there is evidence that different methodologies 
used to assess insulin omission may produce different results. This may be in part 
because participants fear a lack of confidentiality, or judgment from the researcher 
(22). For example, a meta-analysis by Weisband and Kiesler (23) found that 
computer administered assessment methods were associated with increased 
disclosure of personal information. This was particularly with medical patients, and 
specifically when the information was considered sensitive. Third, there is 
inconsistency in the assessment and definition of insulin omission and of insulin 
adherence more widely (1,24). Researchers have attempted to measure this in a 
number of ways. For example, interview methods (25), questionnaires asking for 
responses to series of questions including ‘are you negligent at times about taking 
your insulin medication?’(26), or a single-item – “How often do you skip insulin 
injections that you know you should take?” (2) There is currently no consensus on 
how omission or adherence should be assessed, the time-period that this assessment 
should be based on, or conversely what constitutes good adherence (1,24). This has 
resulted in the lack of an assessment tool available for clinicians to use when 
screening new or existing patients in routine clinical practice for deviations from 
prescribed insulin.   
 
This study aimed to investigate the relationship between insulin omission, self-
efficacy, mood, and diabetes self-management in adults with type 1 diabetes. It 
aimed to address some of the measurement issues outlined by developing a method 
of measuring omission that was anonymous, was designed to be based on findings 
from the limited existing research in this area, and selectively recruited people with 
type 1 diabetes. A type 1 diabetes population was selected due to the comparative 
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scarcity of research on insulin adherence in this group, compared to type 2 diabetes, 
or mixed studies (1,24,27,28) The measure was designed to collect both quantitative 
and narrative data, allowing exploration of the reasons for insulin omission, and 
examining associations with depression and self-efficacy.  
 
Research Design and Methods 
 
This cross sectional web survey included a number of self-report questionnaires that 
were designed to collect both quantitative and narrative data.  
 
Participants and Procedure 
 
Participants were recruited online via a poster advertising a link to the survey which 
was hosted by diabetes related media platforms, including Twitter, Facebook groups, 
and diabetes information websites such as Diabetes UK. Posters were also displayed 
in the waiting room of an NHS diabetes clinic at the Norfolk and Norwich 
University Hospital. Participants were eligible to take part if they were aged 18-65 
years, had a diagnosis of type 1 diabetes for more than one year, lived within the 
European Union (in order that a single ethical legal process could be followed), and 
read fluent English. G* Power version 3 was used to calculate an estimate of the 
number of participants needed for the analysis of quantitative measures based on 
anticipated correlations in order to detect an effect size of 0.2, which indicated an 
appropriate sample size of 191 participants. The study was therefore correctly 
powered. Additional information about the procedure and rationale is provided in 
Chapter 4 – Extended Methodology.  
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Measures 
 
General self-efficacy 
 
The New General Self-Efficacy Scale was used to explore whether a relationship 
similar to the one observed between self-efficacy and diabetes self-management was 
also present between self-efficacy and insulin omission. This eight-item self-report 
measure was found to be valid and highly reliable when compared by the authors 
with other measures of self-efficacy, demonstrating a Cronbach’s α = .85.  Higher 
scores are indicative of greater self-efficacy (26). 
 
Diabetes specific self-efficacy 
 
A measure of diabetes specific self-efficacy was used in order to differentiate 
general self-efficacy from self-efficacy relating specifically to diabetes.  The 
Diabetes Empowerment Scale – Short Form, an eight-item self-report single factor 
scale, was found to be valid and reliable measure of diabetes related psycho-social 
self-efficacy with Cronbach’s α = .84. Higher scores are indicative of greater self-
efficacy (30).  
 
Depression 
 
Measuring depression allowed for the exploration of a quantitative relationship 
between mood and insulin omission in this population. As a measure of depression, 
the Patient Health Questionnaire – 9 (PHQ-9) was used. This nine-item single factor 
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self-report scale was developed, validated, and found to be reliable by Kroeke, 
Spitzer and Williams (31), with a Cronbach’s α = .89, and is widely used in 
healthcare. This measure has more recently been validated for use with diabetes 
patients (32). Higher scores are associated with greater severity of depression.  The 
measure was used as a continuous scale rather than imposing a categorical cut-off in 
order to increase sensitivity, and in response to doubts about the ability of a 
questionnaire measure to appropriately categorise depression in those with diabetes 
(33).  
 
Insulin Omission 
 
An initial questionnaire was developed for the purposes of this study based on 
information drawn from a variety of sources. This included material developed from 
the limited research available assessing insulin omission (2,8,9,16). In addition, new 
items were generated, designed to allow participants to write freely about their 
reasons for insulin omission, and to ascertain any associations with mood. Once the 
questionnaire had been developed, a five-stage consultation process involving 
professionals working in diabetes and patients with type 1 diabetes took place. The 
range, form, and content of the questions were discussed and feedback was obtained, 
with changes made to the measure reflecting this, including the addition of new 
items. The final questionnaire contained 16 questions which assessed insulin 
omission. The frequency of missing doses and the frequency of taking less or more 
insulin than needed was assessed e.g. ‘Do you ever skip (miss out) insulin doses that 
you know you should take?’ ‘Do you ever take less or more insulin than you know 
you should?’ Participants were asked in open ended questions why they engaged in 
  62
this behaviour, in response to the question ‘Could you explain in your own words 
why you skipped an insulin dose that you knew you should take?’, and whether this 
was linked to mood, by responding to the question  ‘Does your mood effect how you 
take insulin?’, and  ‘Does taking insulin effect your mood?’ ‘If so, how?’. Further 
detail on the development of this measure is provided in Chapter 4 – Extended 
Methodology.  
 
Self-management of diabetes 
 
Since this project involved the development of a new assessment tool, the inclusion 
of a measure of diabetes self-management allowed the variables of interest in this 
study to be explored against a previously validated measure. It also allowed for the 
association between self-management and insulin omission to be reported. The 16-
item self-report Diabetes Self-Management Questionnaire (DSMQ) was selected as a 
recent, validated questionnaire that had strong associations with HbA1c levels and 
good internal consistency (overall Cronbach’s α = .84) (34). Participants were asked 
to consider their diabetes care over the last eight weeks, with questions focusing on 
glucose management, dietary control, physical activity, and health care use. The 
questionnaire generated an overall sum-scale, as well as four factors including health 
care-use, physical activity, dietary control, and glucose management. Higher scores 
were indicative of better self-management. 
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Analysis Plans 
 
Quantitative data from the questionnaires were analysed using the statistical package 
SPSS version 22. Bivariate analyses were carried out to identify factors related to 
diabetes self-management and insulin omission. Where data did not meet parametric 
assumptions, non-parametric alternative tests were used in place of parametric 
testing.  
  
Narrative data collected were analysed in a qualitative software package (NVivo 11 
QSR) using thematic analysis (35). Data were read and reread, and categorised into 
key phrases to generate initial codes relating to insulin omission by the primary 
researcher SA. These codes were discussed with BT and SC, and a list of second 
code cycles were created. The data were then reread with the revised coding 
framework applied, leading to a final five themes. Themes were identified at a 
semantic level, and the researchers took an essentialist approach, assuming that the 
language used reflected and enabled meaning and experience to be articulated.  
 
Results 
 
Participant Characteristics 
 
Between August and November 2016, a total of 264 participants provided consent to 
take part in the study. Of these, 231 completed and met the inclusion criteria, and 
took part in the survey, with 171 (78% female 22% male) completing the 
questionnaire. See supplementary figure 1 which depicts this. The responses of 
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participants who withdrew mid-way through a single questionnaire were included in 
analyses providing more than 75% of that questionnaire was completed (missing 
data points were imputed using average scores for the relevant questionnaire).  
 
Supplementary Figure 1: Response rate to online questionnaire 
 
Participants were aged between 18-65, and 95% of those who took part were living 
in the UK. Forty-six percent reported being on an insulin pump, with the remaining 
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54% taking insulin injections. Participants had been on their current regime of 
treatment for an average of 5-6 years, and the mean age fell within the age bracket 
34-41 years old. Approximately 30% (60/201) of responders answered yes to the 
question ‘do you ever skip (miss out) insulin doses that you know you should take?’, 
and were coded in the ‘omission’ group for analyses. Four per-cent (10/201) reported 
they had omitted insulin seven or more times in the last week. Around half (99/199) 
of responders answered yes to the question ‘do you ever take less or more insulin 
than you know you should?’ Forty eight percent (96/201) of responders reported 
either omitting or restricting insulin with 41% (81/199) of respondents reporting 
always taking insulin as they should. See Table 1 for participant characteristics.  
 
Chi squared tests were used for categorical data. Those who those omitted insulin 
were significantly younger than those who did not [χ2 (5) = 17.3].  Differences in 
gender and method of delivery of insulin were not statistically significant in those 
who reported omitting insulin and those who did not. [χ2 (1) = 1.67], and [χ2 (1) = 
3.13] respectively.  
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Table 1: Participant characteristics  
Variable No insulin omission  Insulin omission P value 
Insulin omission 
 
Restricting insulin (not 
overdosing) 
 
Overdosing insulin 
(not under dosing)  
 
Both restricting and 
overdosing insulin 
 
141 (70%) 
 
19 (13%) 
 
 
22 (16%) 
 
 
17  (12%) 
60 (30%) 
 
20 (33%) 
 
 
3 (5%) 
 
 
19 (32%) 
- 
 
- 
 
 
- 
 
 
- 
Gender Female   105 (75%)  50 (83%) .27 
    
Injections  72 (51%)  39 (65%) .09 
    
Age  
 
3.35 (.28) =  
age bracket 34-41 
2.48 (.18) =  
age bracket 26-33 
.004* 
Continuous data are presented as mean (SD) and categorical data as n (%) 
Percentages reported are % participants in each insulin omission group who also fall into the category 
described.  
*P<.01 
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Group Comparisons 
 
Group comparisons were used to investigate differences between those who reported 
omitting insulin and those who did not. Depending on whether data met parametric 
assumptions, either independent samples t-tests (using an adjustment for the 
significance of Levene’s test of homogeneity of variance if indicated) or Mann-
Whitney tests were used. Parametric assumptions results are available in Chapter 5 – 
Extended Results. Insulin omission was related to diabetes self-management scores 
with a large effect size. Differences between those who omitted insulin and those 
who did not were significant across all measures investigated. Those who reported 
insulin omission were more likely to have lower general self-efficacy (p < .001), 
lower diabetes specific self-efficacy, (p< .001), higher depression scores (p < .001), 
and poorer self-management (p<.001). See Table 2.  
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Table 2: Group comparisons using T – test or Mann-Whitney  
Variable No insulin 
omission  
Mean (SD) 
Insulin 
omission 
Mean (SD) 
Test result P 
value 
Effect 
size 
 
Depression 
 
6.05 (5.61) 11.01 (6.95) U =6026 <.001 r = 0.35 
General self-
efficacy 
 
24.46 (4.41) 21.61 (5.37) t(95) = 
3.61 
<.001 d = 0.58 
Diabetes specific 
self-efficacy 
 
29.60 (6.06) 24.53 (7.19) U = 2462 <.001 r = 0.33 
Diabetes self-
management total 
score 
35.88 (5.85) 25.50 (10.15) 
 
t(76) = 
7.41 
<.001 d = 1.25 
   Health care use 
 
8.11 (1.41) 6.40 (2.66) U = 2543 <.001 r = 0.33 
   Physical 
activity 
 
6.20 (2.26) 5.30 (2.50) t(198) = 
2.50 
.013 d = 0.38 
   Dietary control 
 
   Glucose      
management 
5.95 (2.46) 
 
13.04 (2.27) 
4.13 (3.00) 
 
8.15 (3.95) 
t(198) = 
4.51 
 
U = 1199 
<.001 
 
<.001 
d = 0.66 
 
r = 0.57 
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Correlations 
 
Correlations were used to investigate relationships between continuous variables 
across the complete participant sample. Pearson’s correlation co-efficient was 
calculated to measure relationships between depression, general self-efficacy, and 
diabetes specific self-efficacy. Kendal’s tau correlation co-efficient was computed to 
investigate relationships that included diabetes self-management due to the non-
normal distribution of data across this variable. All variables were significantly 
related to all other study variables at the p<.01 level (see correlation matrix 
displayed in Table 3).  Results demonstrated that those with poor diabetes self-
management also had higher depression scores, lower general self-efficacy scores, 
and lower diabetes specific self-efficacy scores. Those with higher depression scores 
also had lower general self-efficacy scores, and lower diabetes specific self-efficacy 
scores. Those with higher general self-efficacy scores also had higher diabetes 
specific self-efficacy scores.  
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Table 3: Correlation matrix demonstrating relationships between study variables  
 Depression Diabetes 
related self-
efficacy 
General self-
efficacy 
Diabetes self-
management 
Depression - r=-.61* r=-.60* 
rτ =-.41* 
Diabetes related self-
efficacy 
 
 - r=.52* 
rτ =.44* 
General self-efficacy   - 
rτ =.32* 
Diabetes self-
management 
   - 
*p<.01 
 
Open-Ended Response Analysis Results 
 
A total of 123 of the 231 respondents to the survey (53%) provided a response to one 
or more of the open-ended questions inviting further comments about insulin. In total 
57 of the 60 respondents (95%) who reported insulin omission also provided a 
comment about why. Over 90% of these comments were encompassed in the 
following five themes, using the six-stage process outlined by Braun and Clarke 
(31): a) Prioritising: Forgetting and the demands of daily lifestyle. This was the most 
commonly reported reason for insulin omission with 57% of those who omitted 
insulin giving this as the primary reason. Respondents reported a variety of lifestyle 
factors such as parenting responsibilities, feeling unable to take a break from work, 
or simply forgetting. b) Diabetes related emotional distress was reported by 15% of 
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those who reported insulin omission. Participants described feelings of resentment, 
frustration, or hopelessness towards their diabetes as reasons for insulin omission. 
Answers indicated a two-directional relationship between mood and insulin 
omission, with 60% of those who omitted insulin reporting that their mood affects 
how they take insulin, 43% reporting that taking insulin effects their mood, and 28% 
reporting both of these. c) Weight control. The use of insulin omission for weight 
control was described by 13% of those in the insulin omission group, making it the 
third most common reason given. Participants reported that they engaged in this 
behaviour to either lose weight, or to prevent weight gain. d) Avoidance: Fear of 
physical effects. Ten percent of participants reported fear based reasons for insulin 
omission, in particular a fear of hypoglycemia, or of injections. e) Adaptive 
responses to managing blood sugar levels were reported by 7%. Participants 
explained that sometimes as part of the effective management of their blood sugar, 
they needed to omit insulin doses, for example before exercise. Table 4 presents 
illustrative quotes of these themes. A more detailed account of the results from this 
question, as well as the results from other questions on the questionnaire, are 
provided in Chapter 5 – Extended Results.  
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Table 4: Quotations from thematic analysis of narrative comments 
Theme Representative quotations 
a) Prioritising: Forgetting and 
the demands of daily lifestyle 
‘Occasionally I am so tired. By the time I go to bed I cannot 
manage to take my injections and meds.’ 
‘Didn't skip but when entertaining or serving a big family meal I 
sometimes put it off until everyone is served then forget.’  
  
b) Weight control  ‘To lower my weight, I have gained a stone and I know as a quick 
fix, running my sugars high will give me a quick weight loss.’ 
‘Taking the insulin can lead to weight gain.’ 
‘In order to reduce current weight and/or to avoid the possibility of 
putting on weight on with increased insulin doses.’ 
 
c) Diabetes related emotional 
distress 
 ‘To be in control of my own body.’ 
 ‘Most of the time it’s because I feel so down about my poor 
control that I don't see the point in trying.’ 
‘Sometimes I get so angry about having type 1 diabetes.’ 
 
d) Adaptive responses to 
managing blood sugar levels 
‘Towards the end of the day. If I have not eaten that much in a day 
I think that my sugar levels will be low enough that I don't need 
additional insulin to cope with the food intake.’ 
‘I had low blood sugar and I wanted to avoid hypoglycemia.’ 
 
e) Avoidance: Fear of physical 
effects.  
‘Anxiety over injections.’ 
‘Was worried I took a hypo and nobody would be there to help 
even though I know deep down I can help myself with hypos.’ 
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Conclusions 
 
A relationship between self-efficacy and insulin omission had not previously been 
investigated, and so this is a novel finding. Participants who omitted insulin were 
more likely to report lower levels of self-efficacy, more depressive symptoms, and 
poorer diabetes self-management. The finding in relation to mood and diabetes 
management is consistent with previous research (16). 
 
The rate of omission and/or restriction (48%) reported in the current study was 
generally higher compared to previous research using similar methods of assessment. 
e.g. 31% and 33% (8,19). The way omission and restriction were assessed (self-
report yes/no with no time scale) was similar to these previous research studies to 
allow for comparison. Previous studies have used different methods of data 
collection (telephone and clinic based interviewer questioning) which did not allow 
for anonymous responding. It is possible that the higher prevalence in this study may 
reflect the anonymous style of data collection, allowing for a reduction in fears about 
disclosure (22,23). The higher rates of (only) insulin omission found in a non-
anonymous web survey by Peyrot et al. (2, 57% compared to 30% in the current 
study) may have been due to the inclusion of people with type 2 diabetes, whom they 
identified were more likely to omit insulin (2).  
 
The relationship demonstrated between self-efficacy and insulin omission found in 
the current study supports previous findings that greater diabetes specific self-
efficacy predicted less omission of medication in those with type 2 diabetes (36). 
The design of the current study did not allow us to infer whether those who were 
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more self-efficacious were more likely to take insulin as prescribed, or whether 
missing insulin doses led patients to feel that they were less efficacious and could 
not cope with their diabetes and life generally. Bandura (13), states individuals will 
engage in activities that they feel able to cope with, and avoid those that perceive 
that they cannot cope with. It may be that when individuals feel unable to cope with 
their diabetes they respond with avoidance of insulin, resulting in insulin omission. 
This view is supported by a number of participants in the study who wrote about 
feeling unable to cope with low blood sugar, or injections, and explained or inferred 
that as a result of this, they subsequently omitted insulin.  
 
This study demonstrates that the relationship between mood and diabetes self-
management is complex, with insulin omission playing a significant role. 
Quantitative measurement showed that those with higher scores on the measure of 
depression were more likely to omit insulin. This supports the findings of Trief et al 
(16), who reported that in their sample, participants with depression were more 
likely to miss insulin doses. Respondents in the current study suggested a two-
directional relationship between mood and insulin omission, with mood affecting 
how participants took their insulin, and taking insulin impacting on the mood of 
participants. The direction of the relationship between mood and medication 
adherence has been studied in type 2 diabetes by Gonzalez et al. (37), who found that 
depression was a risk factor for poor medication adherence. Further research is 
required to establish whether this is also the case in type 1 diabetes, and whether it 
applies to insulin omission.  
 
Recognising the relationship depression and self-efficacy have with insulin omission 
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may encourage clinicians to consider these factors when assessing patients 
presenting with insulin omission, and consider the evidence based treatments that 
might helpfully be applied in such cases (20,21). 
 
The themes generated from the narrative accounts are consistent with existing 
research on insulin omission. Insulin omission is commonly associated with the 
desire for weight control and for the purpose of weight loss (5,8,38), due to the 
excretion of sugar and subsequently calories in the urine when insufficient insulin is 
taken for the food consumed (4). The current study supports this finding with a clear 
theme of ‘Weight control’ emerging. A variety of alternative themes also emerged 
and these are also reflected in previous research. The theme of ‘Prioritising: 
Forgetting and the demands of daily lifestyle’, resonated with the most common 
responses of ‘too busy’ and ‘travelling’ provided in the study by Peyrot et al. (9), and 
also in the domain of ‘Forgetting/Delaying and Forgetting’ reported by Sullivan 
(17). The theme of diabetes-related emotional distress in this study and the 
“stress/emotional problems” category (9) may be capturing a similar patient 
experience, although it is difficult to know given the absence of any detail about the 
nature of the stress or emotional problems in the Peyrot et al. study. The theme in 
this study of ‘Adaptive responses to managing blood sugar’ may be reflected in 
Sullivan’s (17) ‘being in situations where there is limited access to food’, and Peyrot 
et al’s ‘skipped a meal’ (9) both of which might be sensible situations in which to 
omit insulin as part of self-monitoring (7). The findings reported from the narrative 
responses of participants in this study are consistent with previous research however, 
no single study has identified such a range of reasons for insulin omission from a 
participant perspective in a population with type 1 diabetes. The range and variety of 
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reasons given for insulin omission by participants in this study reflects the need for 
interventions aimed at reducing the frequency of insulin omission to be equally 
diverse, to support those for whom this is a problem.  
 
A further outcome of this study is stage one of the development of an assessment 
tool, co-produced with patients and clinicians with experiences of diabetes, which 
provided a measure of insulin omission, insulin restriction, and over dosing. Future 
development of this measure will involve adjustments based on feedback received 
from online responders and a larger study validating the measure before introducing 
it for use in clinical practice. 
 
A potential confounding factor in the study is that the majority of participants were 
recruited online through support groups, which may make them more likely to 
identify with their diagnosis of diabetes, and be more motivated to care for their 
diabetes. Furthermore, women were over-represented compared to men in this 
sample. This limits the generalizability of the findings to the wider population of 
those with type 1 diabetes. Finally, the study did not request an objective measure of 
insulin omission, such a medical monitoring of blood glucose levels, and so the 
inferences drawn are based on self-reported data. However, the potential for 
participants to intentionally misreport this was minimized due to the anonymous 
methodology.  
 
The current study used both qualitative and narrative findings to investigate the 
relationship between insulin omission, depression, and self-efficacy. It is hoped that 
the broader understanding of insulin omission provided can helpfully develop and 
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inform interventions, and facilitate better communication between patients and 
clinicians. Further discussion of these results is available in Chapter 6 – Discussion.  
*********** 
 
The study was approved by the South-West Cornwall & Plymouth Research Ethics 
Committee 
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This chapter will include a description of the ethical considerations for the 
empirical study and report on the construction and development of the measure of 
insulin omission. 
4.1 Ethical Considerations  
Some parts of this section have been minimally changed from the Thesis 
Proposal for this project (Ames, 2015). 
4.1.1. Ethical Approval 
Ethical approval for the study was obtained from the Proportionate Review 
Sub-Committee at South West – Cornwall and Plymouth Research Ethics Committee 
prior to beginning the study. See approval letter documented in Appendix B which 
confirms that this was granted. 
4.1.2 Consent 
Informed consent was taken from participants using Appendices C (patient 
consent to contact form) and D (consent form) for the questionnaire development, 
and Appendix E (online consent form) for the online survey. It was not practical to 
obtain written consent or face-to-face consent for the online survey, given the nature 
of the project, which was designed to be anonymous. 
4.1.3 Confidentiality 
For the questionnaire development, a paper consent form was used and 
signed by participants, which meant that their name was recorded. This information 
is stored securely in a locked file at the University of East Anglia and has not been 
recorded electronically. No personal details were taken from participants during the 
web survey, and so participation was anonymous. Individual responses were stored 
securely online in accordance with NHS confidentiality policy while the research 
was on-going. Following this, individual responses are kept securely at the 
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University of East Anglia and destroyed 10 years after the study has been completed. 
The account will be kept active until July 2017. The primary researcher (SA) and 
supervisors (SC and BT) have access to these details.   
4.1.4 Participant Safety 
The possibility that the survey might elicit distress in some participants was 
considered, in particular from questions about mood and questions about behaviour 
that potentially carries a risk to the participants’ health. To minimise this, 
participants were told about the nature of the questions they would be asked before 
they agreed to take part. Further, participants were informed that they could exit the 
survey at any point, as well as decline any questions they were not happy to answer. 
(see Appendices F-H for participant information sheets). When participants finished 
the survey, or if they chose to exit the survey early, they were directed to a thank you 
page which contained information about where they could access support (Appendix 
I). Given the anonymous nature of the study, it was not possible for the authors to 
contact relevant health professionals about such discoveries, and this was made clear 
in the participant information sheet.  
4.2 Type 1 Diabetes Population 
 As the current empirical paper describes, differences in insulin omission have 
been reported between those with type 1 and type 2 diabetes. Peyrot et al. (2010) 
found that those with type 2 diabetes were more likely to omit insulin than those 
with type 1 diabetes. Further, differences were reported in the risk factors for insulin 
omission between these groups, with diet non-adherence being more prominent in 
type 1 diabetes, and demographic factors such as income, education, and age playing 
more of a role in those with type 2 diabetes. Despite this, research investigating 
insulin adherence or omission is sometimes mixed (e.g. Peyrot et al., 2012b, Peyrot 
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et al., 2012a, Stolpe et al., 2016). This has led to a lack of clarity over whether the 
results apply equally to both diseases.  
A systematic review of insulin adherence measures in those with type 1 and 
type 2 diabetes revealed a substantial bias towards research in type 2 diabetes (Stolpe 
et al., 2016). Only two (2.6%) of the 78 studies reviewed were conducted exclusively 
with people with type 1 diabetes, compared to 58 (74.3%) conducted with people 
with type 2 diabetes. In order to address this gap, the study aimed to develop 
knowledge about insulin omission in those with type 1 diabetes.   
4.3 Insulin Questionnaire Design 
A questionnaire about insulin was developed for the purposes of this study 
and due to the lack of a specific instrument available to assess this. The main aims of 
this questionnaire were to identify those who omitted insulin, and to elicit responses 
from participants in their own words about this. The questionnaire collected 
quantitative data about the prevalence and frequency of insulin omission in adults 
with type 1 diabetes, surveyed online. Other aspects of adherence to insulin 
medication, such as taking less or more insulin than required, and the frequencies of 
these were also assessed, as well as information about links with mood.   
4.3.1 Self-report Questionnaire Design 
 The measure was designed following the current systematic review of 
existing measures of insulin adherence in previous studies. A self-report method was 
selected following the review which revealed self-report measures were the most 
frequently used measurement of insulin adherence, and may be favorable in terms of 
ease of use for both patient and clinician when compared to medical monitoring or 
interview methods (Stirratt et al., 2015). Additionally, questionnaires were the form 
of self-report that correlated most highly with other measures of adherence, such as 
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clinical opinion, claims data, and drug levels (Garber, Nau, Erickson, Aikens, & 
Lawrence, 2004). Shi et al. (2010), in an investigation of the differences between 
self-report and medical monitoring in measuring adherence, found that the majority 
of self-report questionnaires showed high or moderate correlation with medical 
monitoring devices, and recommended considering patient report as a method of 
measuring adherence. Finally this form of assessment was most suitable for an 
online survey. This follows advice from Clifford et al. (2014) to select a 
methodology for measuring adherence to diabetes medication that best fits the 
research question, study design, population, and resources.  
It was identified in existing literature that previous measures of insulin 
omission or adherence did not allow participants scope to explain their reasons for 
either omission or non-adherence. This meant that an opportunity to collect 
potentially important clinical data, which may be beneficial for designing 
interventions to target insulin omission, or insulin adherence more generally, was 
missed.  
Finally, it was observed by the researchers that the language used in some 
self-report measures of insulin adherence may have the potential to feel stigmatizing 
or judgmental for patients with diabetes, for example asking participants if they are 
‘negligent’ (Gomes & Negrato, 2016). Adaptation of these questionnaires was 
therefore considered necessary. 
4.3.2 Open-ended Question Design 
Peyrot et al. (2012a) developed a questionnaire that aimed to investigate 
reasons for insulin omission and non-adherence, (measured by asking participants 
whether they ever miss a dose or take it not exactly as prescribed) via computer 
assisted telephone interviewing. The questionnaire suggested possible reasons from a 
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list that participants could then choose from. However, no information was available 
to indicate the basis upon which these questions were initially selected. Likewise, 
Farsaei et al. (2014) reported a list of possible barriers to insulin omission, including 
for example age, gender, embarrassment, cost, weight gain, and forgetfulness, with 
no information about how these reasons had been devised, including whether they 
had been generated by participants, existing research, or the researchers. It is 
therefore unclear how appropriate or inclusive these pre-selected responses were for 
those with type 1 diabetes as explanations for insulin omission. Further, it is possible 
that suggesting reasons using pre-selected criteria (closed questions) may cue 
respondents into thinking of particular reasons, as discussed by Roberts et al., 
(2014). This was inconsistent with the aims of the study, which intended to elicit 
from participants their reasons for insulin omission.  
4.3.4 Anonymous Methods of Data Collection  
The difficulties of closed questions can be addressed by utilizing more open 
interview methods, as used by Sullivan (2012). However, participants recruited in 
the Sullivan study using interview methods did not report any association with 
mood, and also did not report using insulin as a way to control their weight or shape, 
which has commonly been identified in previous literature (e.g. Trief et al., 2014; 
Polonsky et al., 1994). This discrepancy in findings about the role of mood and 
weight control in insulin omission supports previous evidence that different 
methodologies may produce different levels of disclosure (Lucas, Gratch, King, & 
Morency, 2014). One of the reasons for this is thought to be confidentiality, with 
Singer, Mathiowetz, and Couper, (1993) finding that concerns about confidentiality 
and privacy significantly influenced mail returns on a census. Participants may fear 
that their responses will be disclosed to agencies not directly involved in the 
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research, the reality of which is often made explicit in health research, as contact 
details of a medical professional with responsibility for the participant’s care can be 
requested.  Further, concerns about being judged negatively by the researcher may 
mean that participants do not provide honest, detailed information (Farber, 2006). A 
meta-analysis by Weisband and Kiesler (1996) found that using computer 
administered assessment methods was associated with increased disclosure of 
personal information. They found that these effect sizes were largest when 
comparing computer administration with face-to-face interviews, when participants 
were medical or psychiatric patients, and when the information was sensitive. A 
more recent study by Lucas et al. (2014) also found that when an interview process 
was seen as virtual, or as conducted by a computer, participants reported a lower fear 
of self-disclosure, low impression management, displayed sadness more intensely, 
and were rated as more willing to disclose. To the researcher’s knowledge, no 
questionnaire to date has allowed participants the scope to freely and anonymously 
write about their reasons for insulin omission.  
This study aimed to address these measurement issues by designing a 
questionnaire that was acceptable to patients, measured the prevalence and frequency 
of insulin omission, and collected data about the reasons patients might engage in 
insulin omission to facilitate the development of our understanding of this area. 
Although the primary purpose of this questionnaire was to obtain information about 
insulin omission in response to specific research questions, the researchers held in 
mind that in the future it may also be a useful tool, if modified, for clinicians to use 
when assessing whether their patients omit insulin, and to understand why.  
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4.4 Insulin Questionnaire Development 
4.4.1 Questionnaire Development Stage One 
The initial stage of this process involved collating information from measures 
that had been used in previous studies. This included material developed from the 
limited research available reporting assessing insulin omission such as the questions 
used by Peyrot et al. (2010; 2012b; 2012a), Trief et al., (2014) and Polonsky et al. 
(1994). The questions from the Morisky Medication Adherence Scale (1986) were 
also considered and parts of this questionnaire adapted, as this is a validated and 
often used method of measuring medication adherence by self-report, including in 
studies of type 1 diabetes (Gomes & Negrato, 2016; Stolpe et al., 2016), although as 
discussed in the current systematic review, there are some disadvantages of these 
instruments including the language used, and a lack of opportunity to explain the 
reasons for adherence or non-adherence. Additionally, the Morisky Medication 
Adherence Scale was found to have low sensitivity in a diabetes population by 
Sakthong, Chabunthom, and Charoenvisuthiwongs (2009). From these sources and 
following adaptation, the first draft of a questionnaire was produced that focused on 
asking questions about insulin omission and under-dosing (see Appendix J). 
Questions were phrased first asking about whether participants ever omit insulin, e.g. 
‘Do you ever skip (miss out) an insulin dose that you know you should take’, 
followed by four follow up questions about frequency, requesting information on the 
number of days, and the number of times over the last seven and 28 days 
respectively. There was also a space for participants to provide an answer in 
response to the prompt ‘please explain in your own words why you skipped an 
insulin dose that you knew you should take’. This format was repeated for questions 
on whether participants took less insulin than they should, and whether they forgot to 
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take their insulin. Participants were asked to comment on whether their mood ever 
affected how they took their insulin, and the circumstances under which they would 
be more and less likely to take insulin as they should.  
4.4.2 Stage Two – Consultation 
 Previous health research has highlighted the value of including clinicians and 
patients in the development of a new measure (Van der Molen et al., 2003). It is 
argued that by involving both clinicians and patients at this stage, it allows for the 
representation of items that are relevant to both parties. Leung (2001) also argues 
that the piloting of questionnaires with people characteristic of those the 
questionnaire is for, is a crucial step in any measure development. Therefore, the 
second stage of this process involved consultations with a multi-disciplinary clinical 
diabetes team working from a diabetes clinic and with patients presenting at the 
clinic with type 1 diabetes. Consultation with the diabetes team took the form of a 
presentation that was attended by approximately 20 diabetes specialist clinicians, 
including consultants, junior doctors, specialist nurses, and a specialist clinical 
psychologist. The presentation outlined the research project and included a copy of 
the questionnaire which was given to each attendee for their comments and 
suggestions. Feedback on the scope, form, and content of the questions was 
requested and provided by the team members. 
On the same day, individual feedback was requested from a participant with 
type 1 diabetes who attended the hospital, and a professional with type 1 diabetes 
who worked at the diabetes clinic. Both were directed to the consultation stage of the 
study by the clinical psychologist in the team as individuals who may be interested 
in contributing to this research. It was hoped that more participants with type 1 
diabetes would be identified to take part in this development phase of the study, and 
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the diabetes team were encouraged to provide the participant information sheet and 
consent to contact form to any patients who may be interested in order to facilitate 
this. However only two participants with type 1 diabetes came forward within the 
necessary time-scale and were included. The participants were initially given 
information sheets and time to decide whether they wished to take part, and filled out 
a consent-to-contact form. It was then arranged by email that the primary researcher 
(SA) would meet these participants to obtain feedback on the questionnaires. Written 
consent to take part in the consultation stage of the study was given at the start of the 
meeting.  
4.4.3 Feedback from Staff Team Consultation. Following the presentation, 
the staff team reported with consensus that the questionnaire would benefit from less 
focus on the quantity of insulin doses missed. They reported that the volume of 
questions about this in the original questionnaire could potentially feel judgmental or 
punitive and therefore off-putting to participants.  As an alternative, they suggested 
listing frequencies and requesting that participants select a range from a list, rather 
than being required to remember exactly how many insulin doses they had missed. 
Additionally, clinicians reported that a one-month time scale was likely to be too 
long for participants to recall how many insulin doses they had missed, and that a 
week might be more appropriate. It was also suggested that a validating sentence at 
the start, making reference to the fact that many people miss injections and for a 
variety of reasons, may promote more honest reporting and potentially reduce an 
element of shame. Remaining sections of the questionnaire were deemed to be 
straightforward and clearly accessible to participants. 
Feedback was provided which suggested that if the tool were to be used in 
clinical practice, it would be helpful for clinicians to know which insulin doses were 
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missed by patients or participants, as missing long acting insulin or short acting 
insulin is likely to lead to different clinical outcomes.  
It was thought that, in the question about participants taking less insulin than 
they need, this could be expanded to also capture data about when participants take 
more insulin than they need. The clinicians reported that this is something that can 
also cause complications, that they sometimes experience with their patients, which 
it would be useful area to gather information on.  
The diabetes team were also interested to know whether people who omit 
insulin would discuss this with their clinicians. Capturing this data anonymously in 
the first instance provided an opportunity to give this and other diabetes teams a 
sense of whether their patients feel able to share this information, or ask for their 
help.  
Overall, the team felt that it was important for the questionnaire to ask fewer 
questions about frequency, and more questions about the reasons people engage in 
this behaviour. Given that a number of studies have reported diabetes medication 
adherence frequencies (e.g. reviewed by Clifford et al 2014; Krass, Schieback, & 
Dhippayom, 2015; Cramer, 2004, and also reported by the current systematic 
review) the recommendations from the feedback were implemented. In common 
with clinician reporting, a review of the available literature revealed that there was 
less empirical information available about why people omit insulin (Peyrot et al., 
2012b), and none to the authors’ knowledge that has given participants the 
opportunity to comment on this freely and anonymously without providing pre-
defined response options.   
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4.4.4 Feedback from Participants with Type 1 Diabetes.  
From the individual interviews with participants with type 1 diabetes, further 
feedback was obtained on this initial questionnaire. As part of the process, changes 
that had been suggested by the diabetes team were explained, and feedback was 
requested on these. In general, there was an agreement about proposed changes, and 
no proposed changes were objected to. These participants also suggested that it was 
important to ask about gender, and it was suggested that men may be worse at 
contacting the diabetes team for help. This suggestion was supported by the 
literature, with a review by Galdas, Cheater, and Marshall (2005) revealing that men 
are more likely to delay seeking help for health problems when they become ill. It 
was also suggested that the timing may be important, as participants may be likely to 
miss injections at the same time each day, such as lunch time, for example if they are 
more likely to be out or at work, and therefore busy or distracted, or in the evening if 
they feel too tired to take insulin. Both participants suggested independently that the 
proposed question about mood needed to be asked in both directions, stating that as 
well as their mood affecting whether they take insulin, taking insulin can also have 
an effect on their mood.  
Feedback on the wording used was also provided, for example instead of 
‘please explain’ it was suggested that ‘could you’ or ‘are you able to’, might feel less 
directive for participants. It was also suggested by the diabetes professional who had 
type 1 diabetes that asking ‘what would motivate you to take your insulin as you 
should’ might be a method of collecting data that is important for researchers in 
order to guide interventions, and also important for clinicians to understand what 
might help their patients.  
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4.4.5 Stage Three - Revision 
The questionnaire was substantially adapted based on this feedback. The 
multiple frequency questions were taken out, and replaced with frequency ranges for 
two behaviours: ‘Do you ever skip (miss out) insulin doses that you know you 
should take?’ and ‘do you ever take more or less insulin that you know you should?’. 
Follow up questions included ‘If yes, in the last 7 days was this: less than two times, 
2-4 times, 4-6 times, 7 times or more’, and ‘If yes, could you explain in your own 
words why you skipped an insulin dose that you knew you should take?’ Additional 
questions were included about the timing of skipped doses, the type of dose, and 
whether this was perceived as a problem for the participant. Further questions on 
whether participants informed their diabetes team that they were missing insulin 
doses, and open-ended questions about links with mood were included. Questions on 
what makes participants more or less likely to take insulin as they should, and what 
would motivate them to take insulin as they should were also included in the revised 
version of the questionnaire. The final question in the online survey requested 
feedback on the insulin questionnaire, to facilitate further development of the 
measure.  
4.4.6 Stage Four – Feedback Requested on Changes Made 
A revised version of the questionnaire including the changes made on the 
basis of feedback was sent to the diabetes team highlighting where these changes had 
been made. In response to this, an email was received which gave a suggestion for an 
introduction to the questionnaire ‘Living with diabetes is hard work, practically, 
physically and psychologically. Research tells us that many people miss 
insulin doses sometimes. This questionnaire aims to help us understand why.’  
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4.4.7 Stage Five – Final Version 
 This sentence was added, and the resulting questionnaire was used in the 
online survey. See Appendix K. 
4.5 Treatment of Qualitative Data on Insulin Omission. 
Careful consideration was given to the selection of a method used for 
analysing the data collected from open-ended questions included in the 
questionnaire. The options explored included thematic analysis using the framework 
provided by Braun and Clarke (2006), Grounded Theory (Strauss & Corbin, 1990) 
and Interpretative Phenomenological Analysis (IPA; Smith, Flowers, & Larkin, 
2009). Grounded theory aims to construct a theory through the analysis of data, 
which was not thought to be relevant to the research aims of the current study. IPA is 
an approach which aims to provide a detailed examination of personal lived 
experience, and is tied to a phenomenological position. Given the potential for high 
frequency short answers, this did not seem appropriate for the methodology used in 
this study. The potential future use of the questionnaire as a clinical tool was 
considered, and it was thought that identifying common themes in the answers might 
allow for these to be included as questions or options for a closed-question 
questionnaire in the future. Additionally, the identification of themes would allow 
for a comparison with the categories or options given, or constructs identified in 
previous studies, such as Sullivan (2012) and Peyrot et al. (2012). A thematic 
analysis also offered the advantages of being a theoretically flexible approach, 
meaning that it would not be tied to a particular theory or epistemology. This meant 
that it could be applied across a range of theoretical approaches. On this basis, a 
thematic analysis using Braun and Clarke’s (2006) framework was selected for use 
in this study.  
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An inductive analysis style was used, meaning that the themes identified 
were strongly linked to the data in a ‘bottom up’ way, rather than in a ‘top down’ 
more theoretical and deductive way.  Themes were identified at a semantic level, 
meaning that the researcher focused on the surface meaning of what was written 
rather than attempting to explore deeper meanings.  The author took an essentialist 
approach (Braisby, Franks, & Hampton, 1996), which complements the inductive 
analysis. This approach assumes that it is possible to create theories about meaning 
from language, because of the view that language is a tool which reflects and enables 
us to communicate meaning and experience. Some engagement with the literature 
had taken place prior to analysis in order to identify research questions and the gap 
in the literature that the current project aims to fill. 
The research software NVivo 11 (QSR International Pty Ltd, 2016) was used 
to aid the thematic analysis. This was used to organise, group, and code themes 
together.  
The six steps recommended by Braun and Clarke in their paper ‘Using 
thematic analysis in psychology’ (2006) were followed. This involved first becoming 
familiar with the data through repeated reading and searching for patterns. Data were 
read and reread for any themes that occurred in response to questions ‘can you 
explain in your own words why you skipped an insulin dose that you knew you 
should take?’, as well as looking at the answers of those who reported why they 
sometimes take less insulin than they should. Secondly, initial codes were generated. 
This involved identifying multiple potential themes, and only leaving ambiguous 
data un-coded. This ensured that the analysis did not move away from the semantic 
or surface level meaning of the data. Some of the extracts were coded into more than 
one initial theme. The codes were organized around the frequency of their 
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occurrence in the data, and were not linked to previously found themes or the 
authors’ particular interests in the topic. Phase three involved searching for themes 
within the codes. At this point, different codes were combined in order to form an 
over-arching theme, for example ‘being too busy’ and ‘being distracted’ were coded 
into the broader theme of ‘lifestyle’, as led by the data, while other potential themes 
were discarded. A visual map was created in order to do this (see Appendix L). 
Phase four involved reviewing the themes, reading all the extracts for a particular 
theme, and ensuring that a pattern was present. In phase five the themes were named 
and defined. This was done with the intention of the name immediately informing 
the reader what is captured by the theme. Phase six involved writing up the themes, 
including extracts of participants’ answers.  
4.6 Researcher Position 
The importance of making explicit the position and background of the 
researcher in qualitative research is outlined by Berger (2015). It is argued that the 
character and experiences of the researcher may impact upon their reflexivity, which 
is a strategy for quality control in qualitative research. I am a white British female in 
my late twenties. I have designed and undertaken this research project as part of a 
Doctoral Programme in Clinical Psychology at the University of East Anglia. My 
epistemological position centers around constructivism, I believe that knowledge is 
constructed through experiences, rather than being an objective reality (Raskin, 
2002).  I have a professional interest in Clinical Health Psychology, and had no 
personal or professional experience of diabetes before starting this project. I was 
drawn to the project because of the opportunity to explore the interplay between 
mental and physical health. I hoped to understand patterns, associations, and reasons 
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for insulin omission, and to be able to share this knowledge in a way that would be 
helpful for patients and clinicians.  
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Chapter Five 
Extended Results 
  
  101
 
 
This chapter provides further detail on the results reported in the empirical 
study, and reports additional results not included in the empirical paper due to the 
constraints of the word limit of the selected journal. 
5.1 Data Preparation and Cleaning 
5.1.1 Parametric Assumptions 
 Quantitative data were screened to determine whether parametric testing was 
appropriate. Kolmogorov-Smirnov tests and Shapiro-Wilk tests were conducted in 
order to identify whether the data were normally distributed in the insulin omission 
and non-insulin omission groups. Results were significant for all cases except for 
diabetes specific self-efficacy in the insulin omission group. However, Field (2009) 
states that for large sample sizes, the power of these tests increases, and they are 
likely to be significant when distributions are only slightly different from normal. He 
suggests that in these cases, the skewness and kurtosis statistic be taken into account. 
The further the statistic is from zero, the less normal the distribution is. Brown 
(2016) reports that anything above +1 or below –1 is considered to be highly 
skewed. Therefore, for the measures used in statistical analysis, the skewness and 
kurtosis statistics were initially calculated. If these values were either above +1, or 
below -1, they were considered as not normally distributed, and therefore were not 
tested using parametric statistical tests (which require the assumption that data are 
normally distributed).  
 Another assumption of parametric testing between groups is homogeneity of 
variance. Data for group comparisons were therefore also tested using Levene’s test 
(see Table 5.1). 
 Other assumptions of parametric testing include data being interval or ratio, 
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and scores being independent. These assumptions were considered to be upheld by 
the data based on the questionnaires using scale measurement, and the study design 
meaning scores were independent. 
 
Table 5.1 Parametric testing of study variables used for comparing means 
 Kolomogorov-
Smirnov 
Sig. 
Shapiro-
Wilk 
Sig. 
Skewness 
Statistic 
Kurtosis 
Statistic 
Levene’s 
Sig. 
Depression (no 
omission) 
 
.001*** .001*** 0.92 -0.18 .008** 
Depression (insulin 
omission) 
 
.009** .002** 0.43 -1.02  
General self-efficacy 
(no omission) 
 
.001*** .001*** -0.35 0.26 .03** 
General self-efficacy 
(insulin omission) 
 
.001*** .003** -0.75 0.06  
Diabetes specific self-
efficacy 
(no omission) 
 
.008** .001*** --0.73 
 
 
1.17 .09 
Diabetes specific self-
efficacy 
(insulin omission) 
 
.20 .24 -0.28 -0.39  
Diabetes self-
management 
(no omission) 
 
.001*** .001*** -0.71 0.20 .001*** 
Diabetes self-
management (insulin 
omission) 
 
.03* .03* -0.31 -0.96  
Health care use (no .001*** .001*** -2.16 5.12 .001*** 
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omission) 
 
Health care use 
(insulin omission) 
 
.001*** .001*** -0.83 -0.46  
Physical activity (no 
omission) 
 
.001*** .001*** -0.59 -0.38 .65 
Physical activity 
(insulin omission) 
 
.008** .006** -0.48 -0.32  
Dietary control (no 
omission) 
 
.001*** .005** -0.27 -0.24 .06 
Dietary control 
(insulin omission) 
 
.002** .002** 0.67 -0.31  
Glucose control (no 
omission) 
 
.001*** .001*** -1.44 2.33 .001*** 
Glucose control 
(insulin omission) 
.01** .003** -0.06 -1.31  
Note: * p<.05, ** p<.01, *** p<.001 
 
 As suggested by Field (2009), variables which did not meet the assumption 
of normality, which included depression, diabetes specific self-efficacy, health care 
use, and glucose control from Table 5.1 were analysed using the Mann-Whitney test. 
This is a non-parametric alternative to the t-test, and analyses ranked positions of 
scores in different groups. 
When Levene’s test was significant, providing that the data had not violated 
the assumption of normality, the t – test statistic was used which did not assume 
homogeneity of variance between the two groups (Field, 2009). This was the case for 
general self-efficacy and diabetes self-management. If assumptions of normality 
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were violated, non-parametric tests were used regardless of the significance of 
Levene’s test. This was important given Cribbie, Fikensenbaum, Keselman, and 
Wilcox’s (2012) paper which describes that one-way independent group designs 
have increased type I error and reduced power when data is not normally distributed.  
 
Table 5.2 Parametric testing of study variables used for correlation analysis.  
 Kolomogorov-
Smirnov 
Sig. 
Shapiro-
Wilk 
Sig. 
Skewness 
statistic 
Kurtosis 
statistic 
Depression  
 
<.001** <.001** 0.84 -0.32 
General self-efficacy  
 
<.001** <.001** -.60 0.62 
Diabetes specific self-
efficacy 
.002* <.001** -0.61 0.30 
     
Diabetes self-
management 
 
<.001** <.001** -1.04 
 
 
.71 
Note: * p<.01, ** p<.001 
 
 Table 5.2 demonstrates that only diabetes self-management has a Skewness 
of more than +1 or less than -1. Therefore, as recommended by Field (2009), 
Kendal’s tau was used for correlations with diabetes self-management. This test was 
selected over Spearman’s correlation due to suggestions that Kendall’s statistic is a 
better estimate of the correlation of the population (Howell, 2012). Pearson’s 
correlations were used between the remaining variables, as the parametric 
assumptions were considered to be intact (data were interval, scores were 
independent, and homogeneity of variance was not required). 
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Insulin Questionnaire Results 
5.2 Multiple Choice Answers from Insulin Questionnaire 
5.2.1 Discussing Insulin Omission with the Diabetes Team 
Overall, 44.4% of the 171 participants who responded to a multiple-choice 
question said that they would not speak to their diabetes team if they were missing 
insulin doses. This rose to 51.7% when only including those who reported omitting 
insulin. Of those who reported omitting insulin, 69.0% stated that this was a problem 
for them. This meant that 18 participants (7.8% of sample) reported that omitting 
insulin doses was a problem for them, and also said that they wouldn’t talk to their 
diabetes team about this.  
As well as answering this multiple-choice question, two participants 
commented directly on this issue in the overall feedback section of the questionnaire. 
One participant wrote: 
 It's interesting to be asked these questions as I'm not really honest when it 
comes to speaking to my diabetes team, I feel they can be too judgmental sometimes 
so I make out I'm doing better than I probably am. A lot of it is remembering to take 
the insulin. I work a busy day so I do have a habit of forgetting. Sometime I do not 
see the true importance of skipping a dose, think I can make up for it on the next 
one. 
Another participant commented:  
I think this is more common than the team know. It does affect my mood and 
I am aware of the damage I can do by reducing insulin but you never think it'll 
happen to you. I have no complications from my diabetes, yet. 
Differences in responses to speaking to the diabetes team between men and 
women were also assessed, as during the questionnaire development consultation 
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stage it was suggested that men may be worse at reporting insulin omission than 
women. Results showed that 32.4% of the 37 men who responded would not tell 
their diabetes team if they were missing insulin doses, which rose to 40.0% when 
only considering the answers of the ten who reported omitting insulin. By 
comparison, 47.8% of the 134 women who responded reported that they would not 
tell their diabetes team if they were missing insulin doses, rising to 54.0% when only 
considering the answers of the 50 who reported omitting insulin. Based on the 
information provided, in this sample men were more likely than women to tell their 
diabetes team if they were missing insulin doses.  
5.2.2 Characteristics of Insulin Doses Missed 
Of the 75 participants who responded to the question, “Is there a particular 
dose of insulin you are likely to skip? If yes, which one?” 12.0% responded saying 
their long acting dose, and 18.7% responded saying their short acting dose. The 
remaining answers either said “no” or did not specify a dose.  
A total of 94 participants responded to the question “Is there a time of day 
when you would be more likely to skip an insulin dose? If so, when?”. Of these, 
17.0% wrote the morning, 14.9% reported lunchtime, 7.4% reported snacks during 
the day, 18.1% reported in the evening, and 10.7% reported before bed. The 
remaining answers either said “no”, or spoke about missing doses without providing 
a time of day. Based on these results, the evening was the time of day when the 
highest number participants would be most likely to skip insulin doses.  
5.3 Narrative Data Results 
A total of 123 of the 231 respondents to the survey (53.2%) provided a 
response to one or more of the open-ended questions inviting further comments.  
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5.3.1 Insulin Omission 
In total 57 of the 60 respondents (95.0%) who reported insulin omission in 
the last seven days also provided a comment about why. These were analysed using 
the six-stage process outlined by Braun and Clarke (2006). Over 90% of these 
comments were encompassed in the following five themes: a) Prioritising: 
Forgetting and the demands of daily lifestyle, b) Diabetes related emotional distress 
c) Weight control, d) Avoidance: Fear of physical effects, and d) Adaptive responses 
to managing blood sugar levels. Themes were initially coded using only comments 
given in response to the question ‘could you explain in your own words why you 
skipped an insulin dose you knew you should take’. This was to ensure a focus on 
the research question ‘What are some of the reasons that people omit insulin?’ 
within the final themes reported. Once the themes had been established, they were 
considered in the context of all responses provided, and comments from other areas 
of the questionnaire that were thought to be representative of one of the five themes 
were also included in the analysis. This allowed for a greater depth of understanding, 
for example when evaluating the theme of diabetes related emotional distress, 
additional insight was gained from considering responses to the question: ‘Does 
taking insulin effect your mood? If so, how?’ Additionally, considering the themes 
relating to omission in the context of all the data provided allowed differences and 
similarities between those who reported insulin omission, those who reported insulin 
restriction, and those who reported taking more insulin than they knew they should 
to be explored. Illustrative quotes are provided in Table 5.3.  
a) Prioritising: Forgetting and the demands of daily lifestyle (56.5%). The 
most commonly reported reasons for insulin omission were represented by this 
theme, with over 56% of the response codes being encapsulated here. Although 
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respondents reported a variety of lifestyle factors as reasons for insulin omission, 
such as parenting responsibilities, being unable to take a break at work, or being 
distracted from their routine, the idea that taking insulin was difficult to prioritize 
was implicit or explicit in each. Included in this theme were participants who 
reported that they forgot to take their insulin, without elaborating further or offering 
a reason for this (15.3%). Although not made explicit in the responses, it is 
suggested that some or all of these forgetting responses are related to lifestyle factors 
and priorities described above. This is based on the finding that the respondents who 
wrote additional information when they reported forgetting also wrote about such 
factors by way of explanation. This theme did not present as a reason for taking 
more or less insulin, as no participants who commented about taking more or less 
insulin provided answers that fitted this general premise.  
b) Diabetes related emotional distress (14.5%). A variety of negative 
emotional responses to insulin or to diabetes, such as resentment, frustration, and a 
sense of hopelessness, were cited as primary reasons for omission by nine 
respondents. Some participants described a sense of hopelessness, feeling that 
regardless of their efforts they would not be successful in managing their blood 
sugar, while others described using insulin omission to actively take control, such as 
to choosing to continue like a ‘normal non-diabetic person’ or ‘to be in control of my 
body’. When responding to the additional questions about the impact of taking 
insulin on mood, many participants commented that they feel frustrated and fed up 
with taking insulin, and that taking it can leave them feeling sad, angry, or 
embarrassed. Distress of this nature was not reported as a reason for taking more or 
less insulin by any participants, with the exception of one participant who reported 
once taking excess insulin as an attempt to end their life.  
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c) Weight control (12.9.%). The complex relationship between insulin and 
weight was provided as a reason for insulin omission. Participants wrote about 
deliberate insulin omission leading to desired weight loss, with some describing the 
process of how this happens, reporting that omission resulted in sugar and calories 
being purged rather than absorbed. Respondents also reported that the experience of 
taking insulin can lead to weight gain, and named insulin omission as a method of 
avoiding weight gain, rather than for the purpose of weight loss per se. Individuals 
reported that that they felt they were ‘too fat’, that they felt ‘guilty’ after eating, that 
they were fearful of weight gain, and described insulin omission as an opportunity to 
act on this, with rapid results being achieved. Of note, is that as well as 12.9% of 
those who gave a reason for insulin omission reporting reasons relating to weight 
control, 16.7% of those who gave a reason for insulin restriction also mentioned 
weight loss or weight management. The link between insulin omission / restriction 
and weight control may be indicative of eating disorder psychopathology in these 
cases. 
d) Avoidance: Fear of physical effects (9.7%). This category comprised of an 
avoidance that was reported as being fear based, including fear of the symptoms of 
hypoglycemia and anxiety about injections or pain. Participants mentioned in 
particular a fear of hypoglycemia when alone, in situations such as driving, doing 
‘important tasks’, at night, or in public. This theme was identified in some answers 
about taking more insulin than required also. Two respondents who reported taking 
more insulin than they should state that they did this out of fear of their blood sugars 
levels being high. These participants commented on their fear of the long-term 
complications of high blood sugar, and the implications for their health and family 
life. Fear of the physical effects was reported as the primary reason for insulin 
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omission in 9.7% of those who reported insulin omission, and as a reason for taking 
less or more insulin in 26.4% of cases. 
e) Adaptive responses to managing blood sugar levels (6.5%). The long-term 
management of diabetes requires individuals to be responsive to their blood sugar 
levels and to use insulin, or not do, accordingly. Measuring or anticipating low blood 
sugar, and taking steps to correct this, was reported as a reason for insulin omission 
by 6.5% of respondents. Participants wrote about experiencing low blood sugar 
through exercise or lack of food, or when they have missed previous doses, and 
attempting to manage this through omitting insulin, which if taken would be likely to 
lower their blood sugar even further. Although some reported that this was a mistake 
in retrospect, the sense captured by this theme was of the participants’ intention to 
respond adaptively to a situation where missing an insulin dose might be sensible. Of 
note, of those who reported reasons for restricting insulin and/or taking more insulin 
than they knew they should, 46.3% of respondents reported reasons which appeared 
to be an attempt to adaptively and safely manage their blood sugar. Examples 
include taking less insulin before exercise, when blood sugars are effected by stress 
or temperature, or following an episode of hypoglycemia, and taking more insulin 
when blood sugars have been higher, or when planning to consume more food. Many 
of these participants reported not trusting the recommended dose due to feeling that 
from their experience it would not accurately manage their blood sugar, and so 
adjusting it as they deemed necessary.  
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Table 5.3 Illustrative quotes of reasons for insulin omission by theme.  
Theme Representative quotations 
a) Prioritising: Forgetting and 
the demands of daily lifestyle 
‘Occasionally I am so tired. By the time I go to bed I cannot 
manage to take my injections and meds. Typically I sleep for a few 
hours and then wake up and administer, but sometimes I sleep 
through.’ 
 ‘Would be distracted by my lad - am a single parent and only 
realised I missed it when felt awful later.’ 
‘Unplanned eating or eating nasty party food, or if the office 
provides a buffet lunch.’ 
 ‘Not skipped on purpose. Lead a busy lifestyle.’ 
 ‘Usually my night time levemir because I have been too tired and 
fell asleep before I should of taken it.’  
‘Laziness.’ 
‘I felt it was too much trouble to re-site my pump cannula.’ 
‘Didn't skip but when entertaining or serving a big family meal I 
sometimes put it off until everyone is served then forget.’  
 ‘In a rush or pre-occupied with other task so forgot to take the 
shot.’ 
 ‘Forgetting, not being able to remember. Task is so repetitive on 
any given day I can't know for sure if I have done it or not.’ 
‘Just forgot.’ 
‘I think I can correct it later, and then sometimes forget.’ 
 
b) Diabetes related emotional 
distress 
‘Rather than check bloods and take insulin I prefer to ignore it, 
block it out and continue like a normal non-diabetic person.’ 
‘I felt almost hopeless, as if dosing still wouldn't result in good 
outcomes.’ 
‘Sometimes I just want to forget I have diabetes, sometimes I am 
just fed up of injecting as I have already done it 4 times in 1 day.’ 
‘To be in control of my own body.’ 
‘Sometimes I forget or are so damn sick of my disease that I don't 
want to.’ 
‘Most of the time it’s because I feel so down about my poor control 
that I don't see the point in trying.’ 
‘If I'm feeling low moods sometimes I don't bother and 'punish' 
myself by not taking it.’ 
‘I'm just fed up with diabetes. Even if I do everything right, it is 
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never the same, so you feel you're always doing it wrong.’ 
‘Sometimes I get so angry about having type 1 diabetes.’ 
 
c) Weight control 
 
‘To lower my weight, I have gained a stone and I know as a quick 
fix, running my sugars high will give me a quick weight loss.’ 
‘I was having good results but kept dipping and hypo-ing. In a 
short time I gain weight. This made me feel uncomfortable and fat 
so I reduced my insulin intake on my phone Pod to lose weight 
quickly.’ 
‘I know it helps reduce weight by allowing ska to begin.’ 
‘Cannot stand the thought of the weight gain from my binges.’ 
‘I've taken less when I've eaten too much food and drunk water so 
that I can flush out the sugar and kcal's instead of absorbing them 
and taking the insulin which can lead to weight gain.’ 
‘In order to reduce current weight and/or to avoid the possibility of 
putting on weight on with increased insulin doses.’ 
 
d) Avoidance: Fear of physical 
effects.  
‘Anxiety over injections.’ 
‘Was worried I took a hypo and nobody would be there to help 
even though I know deep down I can help myself with hypos.’  
‘Scared of hypo’s when on my own, so will not take the full dose 
of insulin required for meal or have small snacks without insulin if 
I’m going to be on my own.’ 
‘Scared of running hypo in public.’ 
‘I have pdr in both eyes & have undergone 3 operations to save my 
sight. It is my biggest fear to not be able to see again, to never see 
my children grow up. As I know high blood sugars can contribute 
to poor eye health I have a 'fear' of any blood sugar over 7 mmol. I 
tend to overcompensate for any slightly higher blood sugars on a 
regular basis despite knowing it will lead to a hypo, I just cannot 
bear to see any reading above 7.’ (reason given for taking more 
insulin) 
 
e) Adaptive responses to 
managing blood sugar levels 
‘Towards the end of the day. If I have not eaten that much in a day 
I think that my sugar levels will be low enough that I don't need 
additional insulin to cope with the food intake.’ 
‘I had low blood sugar and I wanted to avoid an hypoglycemia.’ 
‘Did not feel like eating.’ 
‘Because I always drop low during the night if my levels are under 
a certain number at night, despite not even taking insulin.’ 
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‘I often take less insulin than I should because I am a very active 
person and I'm aware that I will probably have up to 2-3 hypos if I 
have either the "correct" amount or over the amount.’ 
*These quotations have been minimally changed for the purposes of clarity and to 
preserve anonymity. 
** Some responses are taken from other areas of the questionnaire if representative 
of the theme. 
 
These findings reflect the variety of reasons that people with type 1 diabetes 
might omit their insulin medication, and are presented visually in a thematic map in 
Appendix L.  
5.2.2 Associations with Mood 
In relation to mood, participants were asked ‘does your mood affect how you 
take insulin?’ and ‘does taking insulin affect your mood?’ Around one third (36.0%) 
of all those who responded, and two thirds (60.0%) of those who omitted insulin 
reported that their mood affects how they take insulin. Additionally, 32.0% of all 
those who responded, and 43.3% of those who omitted insulin reported that taking 
insulin affects their mood. Further 19.6% of all those who responded, and 28.3% of 
those who omitted insulin reported both that their mood affected how they took 
insulin, and that insulin affected their mood. Commonly reported responses about the 
impact of mood on taking insulin were apathy – with reports from participants 
describing that they could not be bothered to check their blood sugar or to take 
insulin, and not caring about the consequences, as well as feeling fed up with taking 
insulin, and responding to stress by taking more or less insulin. Participants also 
explained the way that insulin can affect their mood, with many patients who 
responded to this question explaining a negative effect. This included feeling 
annoyed about needing to take it, feeling sad or angry, or feeling bad about the size 
of the dose, and the fact that lower blood sugar also lowered mood. Some 
respondents reported that taking insulin made them feel better by managing their 
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high blood sugar and the physical impact of this and associated stress. Examples are 
reported in Table 5.4  
Table 5.4 Illustrative quotes for the relationship between mood and insulin omission 
Question Representative quotations 
Does your 
mood affect 
how you take 
insulin? 
‘If I'm feeling down or sad, I don't take it because I don't care what will happen.’  
‘I'm just fed up with diabetes. Even if I do everything right, it is never the same, so you 
feel you're always doing it wrong. When I'm depressed, I feel even less inclined to take 
care of myself. It's too unpredictable, and I need a break.’ 
‘If I'm depressed I can't be bothered with my diabetes.’ 
 ‘Low mood means I'm likely to sleep more, and binge eat when I'm awake but not 
necessarily take my insulin.’ 
‘Sometimes when I'm feeling anxious or depressed and out of control I tend to restrict my 
insulin.’ 
 ‘If I feel anxious I eat more than usual, which results in too little insulin even though I 
take the normal dose. If I`m having a bad day and feeling angry, I take more than normal 
which causes my blood sugar to fall very fast.’ 
‘if I’m feeling good then I’m more likely to care and control my levels.’ 
‘If I'm stressed at having a very high blood glucose reading then I will deliberately 
overdose on quick acting.’ 
 
 
Does taking 
insulin affect 
your mood?  
‘It ruins every mealtime, having to think about how much insulin to take every time. Life 
has lost its spontaneity. Other people also think about it, and I hate burdening other people 
with my issues.’ 
‘Get really frustrated and annoyed sometimes that it's necessary to take it, just generally 
fed up that I can't ever just eat without thinking about consequences of taking or not 
taking.’ 
‘It does. I find a lot of non-diabetics are very judgmental about me injecting in public or 
eating things that are not classed as 'good' for a type 1 on insulin, despite my dietician 
explaining about having a balanced diet’ 
‘Yes if my blood sugars are high i can be tired and short tempered, once I’ve taken the 
insulin I generally feel more energetic and awake.’ 
‘Sometimes it can relieve stress - if I am worried about a very high BG reading then it 
calms me down to know I have acted to bring the levels back down.’ 
‘Too much insulin makes me hyperactive and silly. Too little insulin causes me to be in a 
bad mood and irritable with zero tolerance for others.’ 
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5.2.3 Motivation to Adhere to Insulin Regime 
 In total, 123 (53.2%) of all participants provided a written response to the 
question ‘What makes you more likely to take insulin as you should?’. Additionally, 
116 (50.2%) of all participants provided a written response to the question ‘What 
would motivate you to take your insulin as you should?’. Answers were grouped 
together based on similar topics or words, and reflected a variety of factors reported 
by participants that might motivate them as individuals to take insulin as they 
should. A commonly reported response stated by individuals was that the 
achievement of better results would be motivating for them. Participants commented 
that certainty about hypoglycemia or perfection in blood sugar levels would, or does, 
help them take their insulin as they should. Further, participants wrote about their 
long-term health, reporting that they were motivated to prevent complications in the 
future. Another commonly reported response was support and acceptance. 
Participants wrote about the way that being accepted by both strangers and those 
close to them, and supported by those around them including professionals involved 
in their care would or does help them.  
 Other less frequently reported factors included feeling better in the short-term 
after taking insulin appropriately, more monitoring, lifestyle factors, mood, weight, 
confidence, and being motivated by experiencing high blood sugar. Of note, despite 
eight participants who omitted insulin quoting weight loss as a reason for insulin 
omission, only two said that weight loss/ less weight gain would motivate them to 
improve. Categories and examples are reported in Table 5.5. Frequencies of how 
many responses fell into each category are displayed in Figure 5.1.  
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Table 5.5 Quotations on motivation to take insulin as prescribed by category. 
Category Representative quotations 
Better results ‘Seeing the improvement in levels for the effort put in.’ 
‘Perfect control - not interested unless it's perfect.’ 
‘Achieving good results.’ 
‘Feeling like things are 'going well' with my control.’ 
‘If I could perfectly know what my levels would be in 4-5 hours.’ later and not have to 
worry.’ 
‘Guarantee of no hypo.’ 
 ‘When you can see it's working and my sugar levels are steady and predictable’ 
 
More support 
and 
acceptance 
‘Some encouragement from the healthcare team would be nice, but that never happens.’ 
‘An appreciation and understanding by those around me, so that I don't feel like I'm 
continually fighting an unequal and unfair battle with both my body and their ignorance.’ 
‘If it was more accepted by work colleagues, and when I take time to deal with diabetes it 
isn’t frowned upon, and I am not made to make the time up.’ 
‘I would also be motivated by having a care team member tell me "good job" or "improve 
on this"’ 
‘We have "pump meetings" twice a year. They are a good pick me up we can discuss 
what's working and not working for each individual, you know you’re not alone.’ 
‘A healthcare plan with some goals would help with motivation, but I've never had one’ 
‘Strangers/ others not asking stupid questions, being more educated’ 
 
Diabetes 
equipment 
‘Maybe CGMs would help here as I could mitigate the risk of large changes and bad 
bloods and thus negative mood effects on insulin injecting.’ 
‘Perhaps having pump and so easier to take frequent small doses.’ 
‘Having equipment that I could use discretely when around people and having insulin 
infused.’ 
‘Having an insulin pump definitely, it's way more easy to use a pump in public than an 
insulin pen, an insulin pump have less stigma associated and it's more discreet.’ 
‘Random things, like suddenly winning an insulin pump upgrade or small things like 
getting a medical alert or glucose tablets.’ 
‘Pump attached, it's never out of reach and the working out of doses is done by it, so no 
excuse.’ 
 
Long-term 
health: 
Motivated to 
‘Knowing health risks caused by poor diabetes control.’ 
‘I want to stay healthy: I don't want to get complications and die before my time.’ 
‘I am very aware (to the extent of obsessive) of the potential complications of diabetes - 
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prevent 
complications  
even if my diet is not always ideal I become paranoid if my blood sugars go high as I am 
terrified of what could happen if I get it wrong.’ 
‘Seeing someone ill and realising how important it is.’ 
‘Prevention of complications when I'm older and have a family.’ 
 ‘I am scared of the damage that hyperglycemia can cause, I have seen too many 
amputations, it is scary’ 
 ‘Knowing I still have a chance to save my body from acute and chronic complications of 
diabetes.’ 
 ‘I have a 9 month old daughter and I want to be ok to look after her, I value my life and 
my health, and want to be as healthy as I am physically able to.’ 
 
Short-term 
effects: 
Wanting to 
avoid feeling 
bad 
‘Wanting levels to be close to target to avoid feeling crappy due to too high or too low 
numbers.’ 
‘If I don't I will not feel good.’ 
‘Knowing my blood sugars will be up if I don't and I'll feel rubbish!’ 
‘The idea of feeling awful if I didn't take it.’ 
‘It makes you feel better. The effort is worth it, but a drag at the time.’ 
‘Avoiding feeling sick (nausea is inevitable for me with high blood sugars)’ 
 
More 
monitoring 
‘Seeing my CGM graph significantly affects my behaviour and my motivation to eat 
sensibly and try to maintain decent blood sugars. It has a VERY strong motivational effect 
on me and my behaviour.’ 
‘Another motivator would be having all my data (from my pump and Dexcom) all in one 
spot in an easy to read format so I can see trends and know what to change without having 
to look too hard.’ 
‘CGM helps keep me on track & without it I'm certain my control would suffer 
significantly. Plus I'd never bother keeping written records which I've hated doing 
throughout my life. Puns and CHM automatically record everything so life that huge 
burden to write stuff down which is so time consuming.... And few Dr's ever look at them 
after asking you to keep records yet they criticise if you don't do it. A double bind situation 
you can never win!’ 
‘More regular hba1c testing.’ 
‘Keeping a record of all diabetic related movements in a record diary.’ 
‘I'm using freestyle libre and it is soooo enlightening - it is like having a conversation with 
my bg levels and means I am now making more informed choices.’ 
 ‘Having constant contact [with the care team] and the ability to send data.’ 
‘Reminders that forced me to do it at the correct times.’ 
 
Lifestyle 
factors 
‘I'd love to. But I feel the regime I'm on currently doesn't suit the life I lead. Long-lasting 
insulin is a nightmare to manage. I am active, and the ratios I am on currently often lead to 
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Feeling good 
 
 
 
highs and lows following exercise. I also travel a lot and find it hard to ensure correct 
levels, so I tend to underdose my Levemir. I also occassionally drink alcohol (once or 
twice a month) and this really upsets my levels.’ 
 ‘Living a more relaxed way of life having time and place to control it.’ 
‘Being in my usual routine, but without pressure.’ 
‘Knowing that I'm about to eat and what I'm about to eat.’ 
‘Calm, focused, a none pressured environment I can get on with things.’ 
 
‘Good feelings, being happy and not tired all the time.’ 
‘Feeling happy and positive more often. Diabetes appears to make me feel, in the long-
term, depressed. I would like to have stable mood and a positive outlook.’ 
‘Good energy, the personal determination to say to myself that I am going to keep fighting 
this.’ 
‘When I’m feeling in a positive mood about diabetes.’ 
‘Feeling well, feeling like things are 'going well' with my control.’ 
‘When I'm in a good mood’ 
 ‘Being positive more often, not feeling rushed or embarrassed about my diabetes.’ 
‘Good feelings, being happy and not tired all the time.’ 
 
Weight 
control 
‘Less weight gain.’ 
‘Weight loss.’ 
 
Confidence ‘Knowing that I won't get low blood sugar or feeling more confident to treat one.’ 
‘Confidence to treat hypos on my own.’ 
 
High blood 
sugar 
‘High blood sugar due mainly to cold/flu.’ 
‘When I remember or I start getting symptoms I'm running high so I take down insulin.’ 
‘To get long term blood sugar down.’ 
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Figure 5.1 Categories and frequency of responses for motivation to take insulin 
 
These responses provided a number of motivational factors reported by 
participants which would help, or does help, them to take their insulin as they 
should.  
5.3.5 Feedback on Insulin Questionnaire 
 Suggestions for further improvements to the questionnaire were actively 
sought from participants. In total, 80 (34.6%) of all participants provided a response 
to the penultimate question on the overall questionnaire, which stated: ‘We are really 
interested in your feedback on the Insulin Questionnaire (questions 21-36). Do you 
have any comments about this?’. The most frequently reported suggestion was to 
provide capacity to allow participants to give more detail about their insulin regime, 
such as the effect of technology on insulin control, the opportunity to report on 
previous diabetic control (for example as a teenager), and asking about miss-timed 
doses. Comments were also made on the wording, and overall experience of the 
questionnaire. Some participants (n=38, representing 47.5% of responses to this 
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question) used this space to write reflections about their experiences of diabetes 
generally. Such comments were included in other appropriate sections of the analysis 
or results (for example with mood) as indicated, and so are not also included here. 
The responses which included suggestions given by participants, comments made 
about the questionnaire, and participant’s personal experience of the questionnaire 
are recorded in Table 5.6.  
Table 5.6 Quotations for feedback on insulin questionnaire by category.  
Category Responses 
Suggestions ‘I think that the questionnaire could also specifically question delayed/miss-timed 
bolusing, which can be equally detrimental to the health of the person with 
diabetes.’ 
‘It would be very beneficial if you looked at the psychological aspects and how to 
integrate it into treatment.’ 
‘Might be helpful to put in questions about how you take insulin. My experience 
has been dramatically improved by being on a pump.’ 
‘You don't take account of those using technology & should do!’ 
‘I now have much better control due to onset of complications from poor control 
in my past (Hba1c of 7.6 now, had been up to 14 in the past). You need to ask 
about this to learn from it!’ 
‘It's a bit confusing.  You really need to use words other than "skip (missing)" - if 
you want to distinguish between a deliberate choice not to take insulin and the 'oh 
bwgrie, I forgot to bolus'.  If you want to include both, say so.’ 
 ‘A survey like this would be better face to face to see if you can extract the real 
emotion out of someone instead of behind a screen.’ 
 
Personal 
responses to 
the 
questionnaire 
‘This has actually been very helpful for me: being able to think about, analyse 
and review my own behaviours when administering insulin.’   
‘Made me think about why I take insulin’ 
‘Interesting questions I haven't heard before.’ 
‘This is a great area of the questionnaire and if honest can provide a lot of 
personalised information about diabetes control in real life situations.’ 
 ‘They appear to be quite random and not well thought out in my opinion’ 
‘Don't really understand what these questions are getting at.’ 
‘It made me think a bit more about my diabetes care so thank you’  
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These responses provided helpful suggestions for further adaptation of the 
questionnaire. In particular, they suggested the option for more detail about their 
insulin regime or history to be given, and commented that in some cases the wording 
or clarity could be improved. Of those providing a comment on their personal 
 
Further 
comments 
‘My slight concern for your study is that by circulating it through social media 
you may skew the results. In my experience people on these groups tend to be 
trying really hard to deal with their condition proactively. You may be missing 
people who are less engaged.’ 
 ‘They are really good questions to ask and hopefully this research will help more 
young adults in the future to cope before something bad happens’ 
 ‘I don't think the questions are likely to get many result from me re: insulin as 
was focused on missing doses not on carb counting, adjusting insulin incl sick 
day rules or different doses at different times of the day/month.’ 
‘Reasonable questions to ask, but I am not sure if any 'reliable' conclusions will 
be reached.    I believe that people's insulin taking would depend massively on 
how much they have accepted their diagnosis and their understanding of what 
Diabetes complications may possibly ensue, if they have uncontrolled blood 
sugars.’ 
 ‘Some questions are repetitive’ 
‘Just that there are so many things that affect sugar levels, some with immediate 
effect, some with time delays, whereas the survey reads like there is a definite 
right and wrong. I may miscalculate a dose or forget a dose, but its not 
intentionally wrong.’  
 ‘I'm not sure that the majority of diabetics on insulin deliberately forget to take 
their insulin. The reason being is that you don't feel right.’ 
‘While the questions seem focused on recent behaviour, my skipping and 
ignoring dosing was more further back (over a decade ago).’ 
‘A lot of the questions don't apply in the same way for diabetics using a pump (I 
think)’ 
 ‘Sadly I think a lot of people will lie and not answer honestly in fear its recorded 
somewhere that there doctor can see.’     
‘Bit blunt and black and white. Can have negative feelings but still take proper 
dose at proper time’ 
‘It was quick’ 
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experience of the questionnaire, the majority reporting finding it a helpful exercise 
that encouraged them to think more about their insulin or diabetes care.  
5.4 Recruitment Location 
 In response to the final question ‘where did you hear about this study?’, 
87.3% of the 150 participants who responded reported finding the study online, 
including through Facebook support groups, diabetes.co.uk, or diabetes.org. A 
further 9.3% reported seeing the study at their diabetes clinic, and the final 2.7% 
reported hearing about the study through friends or family.  
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Chapter Six 
Discussion and Critical Evaluation 
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This chapter will provide a discussion of the research findings, including the 
strengths and limitations of the research carried out, the theoretical implications, any 
clinical implications, and directions for future research.   
6.1 Research Aims 
This thesis project was designed to explore insulin omission in adults with 
type 1 diabetes. Several specific research aims were identified, these included: 1) To 
critically review, assess, and evaluate the way that adherence to insulin medication 
had been measured in previous studies. 2) To develop an appropriate measure of 
insulin omission for use in this study. 3) To investigate the relationships between 
insulin omission, general self-efficacy, diabetes specific self-efficacy, depression, 
and diabetes self-management. 4) To investigate reasons for insulin omission. 
6.2 Summary of Main Results 
First, the current systematic review highlighted the relative lack of research 
investigating insulin adherence in an adult type 1 diabetes population. It identified 
that within existing studies, the most common method of measuring adherence was 
by self-report questionnaire. The questionnaires reviewed were not always specific 
to the measurement of insulin, were sometimes worded insensitively, and did not 
allow scope for reasons for non-adherence to be reported. The systematic review also 
identified additional measurement issues, such as the lack of consistency in the 
measurement of adherence, the combining of type 1 and type 2 diabetes populations 
in studies, and the lack of a consistent cut off between what is considered 
‘adherence’ and ‘non-adherence’. It was therefore concluded that a new measure 
which builds upon and develops existing measures of insulin omission would be 
necessary to meet the needs of those with type 1 diabetes. 
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Second, a five-stage questionnaire development process was carried out, 
which aimed to create a measure for assessing insulin omission which addressed 
some of the measurement issues outlined. The measure was designed based on 
findings from the limited previous research in this area, and was used selectively 
with people with type 1 diabetes to avoid the merging of information from 
heterogeneous groups. The stages involved developing a draft questionnaire by 
adapting and building on existing measures, requesting feedback from a multi-
disciplinary diabetes clinical team, requesting feedback from people with type 1 
diabetes, amending the measure based on the feedback, and requesting further 
feedback before the questionnaire was finalised. A 16-item questionnaire was 
produced (Available in Appendix K).  
Third, relationships between insulin omission, general self-efficacy, diabetes 
specific self-efficacy, mood, and diabetes self-management were investigated using 
an online questionnaire survey including the measure of insulin omission developed. 
Results showed that insulin omission was reported by 29.9% of respondents, and 
was associated with lower general self-efficacy, lower diabetes specific self-efficacy, 
higher depression scores, and poorer diabetes self-management. In addition, those 
who omitted insulin were younger than those who did not.  
Fourth, participants gave narrative responses to open-ended questions on 
reasons for insulin omission.  Responses provided were analysed using Braun and 
Clarke’s (2006) six-stage thematic analysis. The themes generated comprised of: a) 
Prioritising: Forgetting and the demands of daily lifestyle, b) Diabetes related 
emotional distress c) Weight control, d) Avoidance: Fear of physical effects, and d) 
Adaptive responses to managing blood sugar levels. 
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6.3 Summary of Additional Findings 
As well as providing evidence in response to the four key aims described 
above, the empirical study generated additional findings of relevance to this project. 
These included a number of quantitative results, including finding that those with 
poor diabetes self-management also had higher depression scores, lower general self-
efficacy scores, and lower diabetes specific self-efficacy scores. Furthermore, those 
with higher depression scores also had lower general self-efficacy scores, and lower 
diabetes specific self-efficacy scores. Higher general self-efficacy scores were also 
associated with higher diabetes specific self-efficacy scores.  
Additionally, further qualitative data collected provided information on what 
might motivate people to take their insulin as they should. These responses included 
experiencing better (or perfect) results from taking insulin, having more support and 
acceptance from close circles well as professionals, having better equipment, an 
awareness of the long-term health complications, feeling better in the short term after 
taking insulin appropriately, more monitoring such as continuous glucose monitoring 
(CGM), and better record keeping and reminders. 
 The insulin omission questionnaire provided additional details on patterns of 
insulin omission. Participants in the sample were more likely to miss their evening 
dose of insulin compared to other times of day, and were more likely to miss their 
short acting insulin dose compared to their long acting dose. Overall just under half 
of participants said that they would not speak to their diabetes team about missing 
insulin doses. In this sample, a greater proportion of the men said that they would tell 
their diabetes team if they were missing insulin doses compared to women.  
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6.4 Links with Previous Literature 
6.4.1 Systematic Review 
Findings from the current systematic review are consistent with those of 
previous reviews of insulin adherence. Clifford et al. (2014) reviewed methodologies 
used to assess medication adherence in type 1 and type 2 diabetes across the age 
range, and commented on the lack of consensus on the best method to measure 
adherence. They called for greater consistency in measurement, including question 
content, recall period, and response options. Stolpe et al. (2016) reviewed 
methodologies used for assessing insulin adherence in a type 1 and type 2 diabetes 
adult population. They outlined the challenges in measurement styles reviewed 
including limited accuracy of the measurement used, complexity of data collection, 
and lack of a validated threshold for good adherence. The current systematic review 
was the first to review studies of insulin adherence in an exclusively type 1 diabetes 
adult population, and revealed similar issues with measurement in type 1 diabetes as 
described in type 2 diabetes or mixed populations. In the current systematic review a 
large variation in the rates of adherences were reported, as well variation in the way 
that adherence was measured including questionnaires, interviews, databases, and 
medical monitoring, and within questionnaires in the way that questions were 
worded. Further, there was a lack of measures that were empirically validated as 
questionnaires for use in measuring insulin adherence in type 1 diabetes.  
The current systematic review found the most commonly used method for 
measuring adherence in type 1 diabetes was patient self-report, using questionnaire 
methods in particular. Clifford et al. (2014) reported a similar finding, with 37 
(61.7%) of their total 60 studies using a patient self-report measure. In addition, they 
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found that all of the 14 type 1 diabetes studies they reviewed used some form of self-
report, with none of these using a pharmacy database measure of adherence.  In 
contrast, Stolpe et al. (2016), who reviewed only two studies of type 1 diabetes, (the 
remaining 76 being either type 2 diabetes or mixed populations), reported the most 
commonly used method of measuring adherence was medications possession ratio. 
This is a calculation using prescription data from pharmacy claims databases, 
whereby the total days’ supply of all prescriptions in a defined period are divided by 
the number of days in the defined period. They found that the top five most common 
methods of measuring adherence all used data from pharmacy claims databases, with 
a self-report questionnaire being the sixth most common method of measurement. 
While pharmacy claims databases have commonly been used for measuring 
medication adherence in type 2 diabetes or mixed populations, they have rarely been 
used for this purpose in type 1 diabetes. It may be that, given the greater numbers of 
people with type 2 diabetes compared to type 1 diabetes (Diabetes UK, 2017d), 
pharmacy claims databases are a more popular way of collecting the large amounts 
of data available about adherence in this population. Stolpe et al. (2016) state that 
calculating adherence using a pharmacy database is relatively easy, and therefore 
may be attractive to researchers for this reason. However, they also point out that the 
presence of a pharmacy claim does not necessarily indicate that the medication has 
been taken. This method also does not allow for any exploration or understanding of 
non-adherence of insulin. The discrepancy in findings between measurement of 
adherence in type 1 and type 2 diabetes highlights the need to separate these 
conditions when reviewing research.  
The current systematic review highlighted that within the measurement of 
insulin adherence there was little or no opportunity for participants to comment on 
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why they were non-adherent, including not being able to report if they were 
adaptively taking less or more insulin than prescribed. There is an assumption that if, 
for example, participants collect less insulin from the pharmacy than they require, or 
state that they sometimes take less insulin than prescribed, that this is a maladaptive 
response. While it is the case that restricting or omitting insulin has been associated 
with worse clinical outcomes (Goebel-Fabbri et al., 2008) the self-management of 
diabetes requires individuals to manage their blood sugar levels in response to a 
number of different potential variables. It may therefore be the case that some 
individuals who were appropriately missing insulin doses in response to for example, 
a low blood sugar reading, were included with this group. This potential for merging 
both appropriate and inappropriate self-management behaviours as negative has been 
a criticism of other measurement in diabetes adherence (Martyn-Nemeth, Farabi, 
Mihailescu, Nemeth, & Quinn, 2016), and existing measures of insulin omission did 
not appear to control for this.  
6.4.2 Insulin Omission Prevalence 
The insulin measure developed during the five-stage process was designed to 
address these issues, and focused on insulin omission (missing out insulin doses) as a 
subsection of insulin adherence (taking insulin as prescribed), as well as measuring 
insulin restriction (taking less insulin than required) and insulin over-dosing (taking 
more insulin than required). The rate of insulin omission and/or restriction reported 
by participants using the current study measure (47.8%) was higher compared to 
previous research e.g. 33.2% by Peyrot et al. (2012a) and 30.5% by Polonsky et al. 
(1994). It is possible that the higher rate reported in this study is due to the 
opportunity for anonymous responding which may have facilitating increased 
disclosure from participants (Singer et al., 1993). The higher rate of insulin omission 
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(only) reported by Peyrot et al. (2010) (57.0% compared to 29.9% in this study) may 
be due to the inclusion of people with type 2 diabetes, since this population was 
found to be more likely to omit insulin (Peyrot et al., 2012b).  
6.4.3 Depression 
The relationship found in the current empirical paper between insulin 
omission and depression ratings is consistent with the results of Trief et al. (2014), 
who reported that, in their sample, participants with depression were more likely to 
miss insulin doses. This finding is in contrast to results reported by Peyrot et al.’s 
study (2012b), which found no link between a history of depression and insulin 
omission. Depression status in the study by Peyrot et al. (2012b) was characterized 
by the response to a yes or no question about a history of depression, which is likely 
to be a less sensitive measure of depression than the present day focused and 
continuous measure used in the current study (the Patient Health Questionnaire 9; 
PHQ9; Kroenke, Spitzer, & Williams 2001). Current findings and those of Trief et 
al. (2014) also contrast with the findings from Sullivan (2012) who, using an 
interview study, found that depression was not reported as a main reason for insulin 
omission. This variability in the findings on the nature of the relationship between 
depression and insulin omission may be a reflection of the measurement used, for 
example the use of the PHQ-9 (Kroenke et al., 2001) and the use of a large sample 
size are common to the current study and that of Trief et al. (2014). This contrasts 
with the use of a depression history (defined by responses to 1 question) (Peyrot et 
al., 2012b) and the use of a small sample size and interview methodology (n=13) 
(Sullivan, 2012).  
Further, the association between depression and diabetes self-management in 
people with people with type 1 diabetes has been established in previous research. 
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For example, depression has been found to be associated with poorer self-
management of diabetes, measured by poorer medication adherence, very infrequent 
exercise, non-healthy diet, more smoking (Lin et al., 2004), and poorer hbA1C levels 
(Ciechanowski, Katon, Russo, & Hirsch, 2003).  
Unlike the Trief et al. (2014) paper, the current study did not attempt to 
define a clinical cut off for depression for either diagnostic or group comparison 
purposes, analyzing scores instead along a continuous scale. This decision was made 
due to a number of criticisms about the way depression had been diagnosed in 
people with diabetes, with studies (e.g. Gonzalez, Kane, Binko, Shapira, & 
Hoogendoorn, 2016) outlining the over-identification of depression in those with 
diabetes. Fisher et al. (2010) found that most patients with diabetes and high levels 
of depressive symptoms on a questionnaire did not meet criteria for major depressive 
disorder. It was therefore felt that to use a ‘depressed’ versus ‘non-depressed’ group 
would be unhelpful and potentially misleading, and scores in the current study were 
analysed along a spectrum of low mood instead. Fisher et al. (2010) suggest that the 
questionnaire measure of depression used in their study, a 20 item self-report scale, 
may in fact be more reflective of general emotional and diabetes specific distress 
than clinical depression.  
6.4.4 Self-efficacy 
Self-efficacy is an individual’s belief in their abilities to carry out behaviours 
(Bandura, 1982), and is measured both as general self-efficacy and specifically in 
relation to diabetes in the current empirical paper. A relationship between insulin 
omission and self-efficacy had not previously been established, and so the finding 
that insulin omission is associated with both general and diabetes specific lower self-
efficacy is novel. Sarkar, Fisher, and Schillinger (2006) investigated self-efficacy in 
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relation to diabetes self-management in type 2 diabetes in an interview study, and 
separated self-management into different domains of diet, exercise, self-monitoring 
of blood glucose levels, and medication adherence. Medication adherence was 
assessed by asking about whether any diabetes pills had been missed in the previous 
week. They found that in this population, increases in self-efficacy as measured by a 
four-item self-report questionnaire, were not associated with greater medication 
adherence, but were associated with improvements in diet, exercise, and self-
monitoring of blood glucose levels. Aljasem, Peyrot, Wissow, and Rubin (2001) 
found that in their self-report questionnaire study that greater self-efficacy predicted 
less frequent skipping of medication in those with type 2 diabetes. This finding is 
distinctive from insulin omission because those with type 2 diabetes may not need to 
take insulin, and may take other medications (oral hypoglycemia agents) in pill form 
(Inzucchi, 2002). They also found that self-efficacy predicted more frequent blood 
glucose testing, less frequent binge eating, and greater adherence to an ideal diet. In 
the current empirical study the finding of a relationship between better general and 
diabetes specific self-efficacy and better diabetes self-management support the 
association between self-efficacy and diabetes self-management found in the studies 
described. However, the findings, diverge from those of Sarkar et al. (2006) by 
demonstrating a clear relationship between insulin omission, (an aspect of 
medication adherence), and both lower general self-efficacy, and lower diabetes 
specific self-efficacy. Differences between the current study and the Sarker et al. 
(2006) study include the participant population and types of diabetes, different 
measures of self-efficacy and medication adherence including potentially different 
medications, and differences in methodology. Sarker et al. (2006) suggest a possible 
reason for the lack of relationship between self-efficacy and medication adherence in 
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their study may be that that medication adherence was not accurately measured by 
the self-report interview methodology. Garber et al. (2004) report that interview 
methods have poorer associations with other measures of adherence such as clinician 
report and medical monitoring when compared to questionnaire methods. They 
suggest that this may be due to the greater level of specificity in questionnaires 
compared to interviews, or because of the greater perception of anonymity afforded 
by questionnaires. It is possible therefore that the significant association between 
medication adherence and self-efficacy found in the current study and by Aljasem et 
al. (2001) reflect the questionnaire assessment of medication adherence compared to 
the interview methods used by Sarker et al. (2006), although the differences in 
populations might also account for the disparity in findings.  
The relationship found in the present study between elevated scores on a 
measure of depression and lower self-efficacy is consistent with previous research in 
this area. For example, Flett, Panico, and Hewitt (2011) found that adolescents with 
elevated depressive symptoms also had lower levels of self-efficacy, while Phillips 
and McAuley (2013) found that depression and self-efficacy were correlated when 
examining fatigue in breast cancer survivors. This has also been investigated 
specifically in type 2 diabetes, with Sacco et al. (2005) finding that self-efficacy and 
depression were associated with each other and with diet and exercise adherence in 
this population.  
6.4.5 Reports of Reasons for Insulin Omission 
The themes generated from the narrative accounts about insulin omission are 
also consistent with previous research. The theme which encapsulated the largest 
number of responses from participants (56.5%) was ‘Prioritising: Forgetting and the 
demands of daily lifestyle’. This included participants’ accounts of being too busy, 
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being distracted, forgetting, delaying and then forgetting, being out of their routine, 
or being too tired to take insulin. Similar results were found in the Global Attitudes 
of Patients and Physicians in Insulin Therapy (GAPP), a multi-national survey of 
patients and providers using computer-assisted telephone interviewing (with 
patients) and internet surveying (with physicians). The results of this reported by 
Peyrot et al. (2012a) demonstrated that being ‘too busy’ and ‘travelling’ were the 
most popular responses selected by patients as reasons why they might miss insulin 
doses. Forgetting was the seventh most popular response selected by patients, while 
physicians rated it eleventh, rating being ‘too busy’ and ‘travelling’ in the top three 
reasons for insulin omission as reported by their typical patient.  This finding is also 
compatible with the results of Sullivan (2012), who reported that for 11 of 13 
participants interviewed, ‘forgetting’ or ‘delaying and then forgetting’ were 
described as a reason for insulin omission. Captured within this domain, Sullivan 
illustrates the participants’ accounts of being “too busy”, being “distracted”, or being 
“on the go”, which were also described by participants in the current study in this 
dominant theme.   
Although lifestyle factors are described by these studies, Sullivan (2012) 
comments on the possibility of psychological reasons for “forgetting” to take insulin. 
Non-acceptance of diabetes, underestimation of the need to take insulin, or a 
resistance to the idea of taking insulin regularly are proposed as potential 
explanations for forgetting (Sullivan, 2012). Brod, Kongso, Lessard, and Christensen 
(2009) discuss psychological insulin resistance, defining this as “psychological 
opposition towards insulin use in both people with diabetes and their prescribers” 
(p.29). It is possible that such factors, although not always explicitly described, may 
play a part in patients forgetting to take their insulin. In support of this, some 
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participants in the current empirical study wrote about forgetting being related to 
mood, for example one participant wrote: “When I'm having down days and feeling 
a bit sorry for myself I tend to "forget" I have diabetes” while another wrote 
“Sometimes I just want to forget I have diabetes, sometimes I am just fed up of 
injecting as I have already done it 4 times in 1 day”. However other participants’ 
responses appeared to be less emotionally driven for example, one participant 
commented as a reason for insulin omission: “Forgetting, not being able to 
remember. Task is so repetitive on any given day I can't know for sure if I have done 
it or not”. Studies of forgetting have also linked forgetting medication to age and to 
levels of activity (Neupert, Patterson, David, & Allaire, 2011), and have 
demonstrated in a type 2 diabetes sample that a simple regular text reminder 
improved long-term adherence to oral medication (Vervloet et al., 2014). It is 
possible that “forgetting” encompasses a range of factors for different patients at 
different times, and that although widely acknowledged, our understanding of the 
complexities of this may currently be limited and therefore an area for future 
research.  
The second most common reason for insulin omission in the current study 
was labelled as diabetes related emotional distress. This theme covered a range of 
negative emotional responses to diabetes, including a sense of hopelessness, anger, 
resentment, and frustration with diabetes or insulin. Peyrot et al. (2012a) offered the 
pre-selected answer of “stress/emotional problems” as an option for why a 
participant omitted their insulin. This was selected by patients as the fourth most 
common reason for omitting insulin, and by physicians as the fifth most common 
reason in their typical patient. This category may have captured some of the same 
reasons described by participants in the current study, although this is difficult to 
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conclude given the absence of detail about the nature of the stress or emotional 
problems. However, distress was not reported as a significant theme by Sullivan 
(2012), and equally was not captured by Farsaei et al. (2014), with the exception of 
‘embarrassment’ as a barrier to insulin adherence, which was not described further.  
Diabetes related emotional distress is a recognised construct within diabetes 
care, with Polonsky et al. (2005) developing a “Diabetes Distress Scale” in order to 
measure “emotional burden”, “physician-related distress”, “regimen-related 
distress”, and “diabetes-related interpersonal distress”. The theme in the current 
study differs from this construct in that it captured those who reported wanting to 
reject or deny their diabetes, were embarrassed about injections, described low 
mood, stress, or reported feeling controlled in response to their diabetes, and did not 
capture any physician-related distress. It is of interest that although diabetes related 
distress as a quantifiable construct has been linked to glycemic control (Fisher et al., 
2010), it has not previously been linked to insulin omission as described in the 
current study. Snoek, Bremmer, and Hermanns (2015) wrote about the related but 
distinct constructs of depression and diabetes distress in those with diabetes. They 
comment that there is some overlap between depression and diabetes distress, but 
ascertain that the two are not interchangeable constructs. Both diabetes distress and 
depression have been linked with poorer glycemic control as discussed, however it is 
likely that the underlying pathways differ. While depression is a mood disorder 
defined by the presence of a number of symptoms, and not defined by a particular 
cause (DSM-5; American Psychiatric Association, 2013), diabetes related distress is 
linked specifically with the experience of having diabetes (Polonsky et al., 2005). 
Snoek et al. (2015) found that while depression and diabetes related distress were 
independent factors, their findings suggested that there was some overlap and that 
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depression was an amplifier for diabetes related distress. This means that those who 
experienced depression also tended to experience worse diabetes distress. This 
overlap was considered in relation to some of the qualitative findings that fell into 
the diabetes related distress category that were also relevant to depression, such as a 
sense of hopelessness. 
The third most commonly reported reason for insulin omission was captured 
by the theme of weight control. Participants wrote about a fear of weight gain related 
to taking insulin, and of insulin omission as a fast way to achieve weight loss. By 
omitting insulin, glucose cannot be absorbed by the body and is passed out in urine, 
resulting in the excretion of large amounts of calories (Crow, Keel, & Kendall, 1998; 
Schmitt, 2013). Purging calories in this way may meet the criteria for bulimia as 
specified by the diagnostic and statistical manual of mental disorders (DSM-V; 
American Psychiatric Association, 2013), which specifies “recurrent inappropriate 
compensatory behaviours in order to prevent weight gain such as… misuse of 
laxatives, diuretics, or other medications” (p. 345). The relationship between insulin 
omission and eating disorder psychopathology has been well documented, with the 
title ‘diabulimia’ becoming a recognised term in clinical practice (Ruth-Sahd et al., 
2009). Most research in this area has focused on adolescent females (e.g. Polonsky et 
al., 1994), and rates of insulin restriction for weight loss in adult males and females 
with type 1 diabetes were reported by Bryden et al. (1999) who found this behaviour 
in 30% of females and no males.  Polonsky et al. (1994) found that in their sample of 
females with type 1 diabetes aged 13-60, around 15% reported intentional insulin 
omission for the purpose of weight loss. The rates of insulin omission or restriction 
for weight loss in the current study were lower than this, representing approximately 
4% of the study sample, 13% of those who omitted insulin (0 males, 8 females), and 
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17% of those who restricted insulin (2 males, 7 females). It is possible that the 
smaller prevalence of weight related insulin omission in the current study is due to 
the older population sampled (average age 34-41 years), given that both Peyrot et al. 
(2012b) and the current study found that those who reported omitting insulin were 
more likely to be younger.  
In regard to the fourth theme generated from participants’ “Avoidance: Fear 
of the physical effects”, a review by Martyn-Nemeth, Farabi, Mihailescu, Nemeth, 
and Quinn, (2016) found 53 studies which investigated fear of hypoglycemia in an 
adult diabetes population. They concluded that a fear of hypoglycemia is a problem 
in that it negatively influences diabetes management and quality of life. Further, a 
review by Fu, Qui, and Radican (2009) found six studies which investigated a fear of 
insulin or fear of injections in people with diabetes, which was also encapsulated in 
the current theme. The review concludes that these fears are present and are 
associated with poor glycemic control and physical complications, including an 
increased risk of mortality. Of note, Farsaei et al. (2014) found that fear of 
hypoglycemia did not impact insulin adherence using a telephone survey, which 
contradicts the descriptions given by participants in the current study, many of whom 
state that fear of hypoglycemia is their primary reason for omitting insulin.  
The final theme generated from participants’ responses of ‘Adaptive 
responses to managing blood sugar’ is reflective of some participants appropriately 
and safely omitting insulin. Many participants noted that they administered less 
insulin if they were planning to exercise, if they missed a meal, or in response to a 
low blood sugar reading. Diabetes clinicians may recommend administering less 
insulin in these circumstances as part of the monitoring and self- management of 
diabetes (Stetson et al., 2011). This theme may be captured in Sullivan’s (2012) 
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domain of “being in situations where there is limited access to food” and “planning 
to be physically active”, Peyrot’s (2012a) category of “skipped a meal”, and Farsaei 
et al.’s (2014) barrier of “episodes of hypoglycemia”, for all of which missing an 
insulin dose may be an appropriate and adaptive response. This is indicative of 
omission being positive and beneficial, which challenges the prevailing perception of 
insulin omission in the literature as a negative behaviour. It highlights times when 
‘insulin omission’ may in fact be ‘self-management’, as individuals omit insulin in 
order to safely manage their disease as recommended by clinicians.   
Although the ideas captured in the themes generated by the current study 
have some representation in existing research, no study to our knowledge has 
investigated insulin omission in such a systematic way incorporating quantitative 
and narrative methods.  This research also builds upon areas that previously may 
have been confounded by the discrepancies in findings, methodology, and the 
inclusion of different populations of participants with diabetes.  
6.4.6 Additional Findings from Insulin Measure 
The results from the question about what would motivate people to adhere 
more closely to their insulin regime are mirrored by Kyngas (2007). In a study with 
adolescents, it was found that support from clinicians, internal motivation and 
energy, and the threat to physical wellbeing all predicted good adherence. Lin and 
Ciechanowsk (2008), summarising reviews of clinical trials aimed at achieving 
better medication adherence and diabetes outcomes, recommend that clinicians 
clearly explain key information when prescribing medications, assess adherence in 
an empathic and non-judgmental way, simplify medication taking, identify barriers 
to medication taking, and provide behavioural support. This may be reflected in the 
findings from in the current study of ‘more support and acceptance’, and ‘lifestyle 
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factors’, where participants report feeling judged by others, and finding their 
diabetes regime does not fit with their daily life, respectively.  
‘Despite the findings that participants reported omitting, restricting, or 
overdosing on insulin medication, many participants (40.7%) reported always taking 
insulin as they should. This indicates that despite its complexity, many people do 
manage to adhere to their insulin regime. It is of note that a number of participants 
reported a fear-inducing narrative for maintaining adherence e.g. “I don’t want to get 
complications and die before my time”. It is possible that, given the perceived threat 
of non-adherence (e.g. early death), acknowledgment of a problem which could lead 
to this would be difficult for patients to accept internally and tell their health 
professionals. van Steenkiste et al. (2004) discuss a barrier to change in coronary risk 
as patients denying their risk or ‘sticking their head in the sand’ (p. 43). It is possible 
that this may also be the case for some patients with diabetes, that denial or 
avoidance may be easier than acknowledging openly that they are carrying out a 
behaviour which could have such serious consequences.’ 
Furthermore, of note is that some variables of interest are mentioned in the 
literature as important but were not reported by participants in this study. For 
example, participants in this study do not mention cost, which has been consistently 
reported as a barrier to insulin omission (e.g. Farsaei et al., 2014; a review by Davies 
et al., 2013). This is likely to be due to the majority of participants being from the 
U.K, and therefore being entitled to use the National Health Service (NHS).  
Additionally, gender and delivery of insulin (e.g. injections or insulin pump 
or pen) have been associated with insulin omission in previous research (Pickup et 
al., 2002), and neither were found to be related to insulin omission in this study. In 
addition, in this self-report and anonymous study men reported that they were more 
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likely to tell their diabetes team about missing insulin injections, compared to 
women. These differences challenge such existing research (e.g. Caldas, Cheater, & 
Marshall, 2005), and add to the limited evidence base about insulin omission.  
6.5 Strengths and Limitations  
The current research has a number of strengths and limitations, and it is 
important that the results described are considered in light of these.  
First, a strength of the research was the systematic evaluation of existing 
measures of adherence to insulin medication, which allowed for the strengths and 
weaknesses of each approach to be fully considered, and was invaluable in informing 
the development of the current insulin omission measure. ‘The final review of 
existing studies described in the systematic review took place in December 2016. 
However multiple closely related searches and appraisals of this literature were 
carried out from June 2016 as part of the research process for the systematic review, 
which also informed the empirical paper, and contributed to the development of the 
measure used.  The issues in measurement highlighted in this review could then be 
addressed in the design of the new measure. Adapting and building upon existing 
measures ensured a degree of consistency with previous research, which was 
identified as lacking between studies in this area (Stolpe et al., 2016; Clifford et al., 
2014).  
Involving patients and clinicians in the co-production of the insulin 
questionnaire increased acceptability of the questions and wording, as well as 
attempting to ensure that the questions were focused on areas relevant to those the 
questionnaire was designed to help. Multiple stages of review and feedback 
contributed to the development of a tool that can, with further modification, be used 
in clinical practice.  
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A further strength of the research was the anonymous design utilized for the 
empirical study. Research has indicated that using computerized methods and 
methods consistent with the perception of anonymity result in greater levels of 
disclosure, possibly because of reduced concerns about confidentiality, and less 
impression management. (Lucas et al., 2014; Weisband & Kiesler, 1996). Different 
methodologies used for investigating insulin omission had previously given different 
results (e.g. Peyrot et al., 2012a; Sullivan, 2012), and it was hypothesized that an 
anonymous design might aid clarity by enhancing levels of disclosure. The higher 
levels of insulin omission and restriction found in the current study compared to 
other studies in type 1 diabetes, raises the possibility that participants may have 
previously been under-reporting this. Additionally, the range of reasons found for 
insulin omission had not been reported by any other single study investigating this.  
However, in clinical practice, responding cannot be anonymous, and as 
indicated by the results, participants may not always feel able to discuss these 
difficulties with their clinicians. It is hoped that an awareness of this barrier, as well 
as a clearer understanding about why people might engage in insulin omission, may 
guide clinicians in their clinical questioning, facilitating a more open discussion with 
the intention of better supporting the patient. 
A third strength of the research was the large number of participants 
recruited. which allowed sufficient statistical power for all of the planned analyses to 
be conducted. In addition, the views of many participants were captured in response 
to the open-ended questions, increasing the generalizability of the findings. Given 
that the majority of participants live in the United Kingdom (UK), the results of this 
study are therefore relevant to clinical practice within the UK, allowing for clear 
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Balanced with the study strengths are a number of limitations which are 
considered next.  One limitation of the research was the possible rejection of some 
studies measuring insulin omission and adherence from inclusion in the systematic 
review. Due to the criteria for including and excluding papers, a number of measures 
of insulin adherence and omission that had been used in mixed diabetes populations, 
and with children, were not considered (e.g. Peyrot et al 2012b, Peyrot et al 2012a, 
Polonsky, et al., 1994) This meant that in the development of the questionnaire for 
the empirical paper, while additional papers were taken into account, they were not 
integrated systematically with other adherence measurement which may have aided 
the development process. However, by intentionally focusing on measures used in 
type 1 diabetes this illuminated the lack of specific measurement for this population, 
as well as the discrepancy in the number of research studies in this area between type 
1 diabetes and type 2 diabetes, which supported the design of the current study. 
Further, the review was limited to the databases searched, and was carried out by one 
researcher, both of which increased the potential for bias in selection and for studies 
to be overlooked. 
A further limitation of the study was the lack of depth and detail in the 
narratives collected through open-ended questions. Although some participants gave 
more detailed responses, the majority answered with a single sentence and 
sometimes a single word. This therefore made the planned analysis at the semantic 
level (Braun & Clarke, 2006) challenging, particularly in the case of ambiguous 
answers, for example when participants wrote only ‘I forgot’. Following guidance in 
Braun and Clarke’s paper, which instructs that a deeper level of meaning should be 
considered and hypothesized even when using a semantic approach, these answers 
were grouped according to patterns across the data more broadly (e.g. that most 
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answers that mentioned forgetting also mentioned lifestyle reasons). However, the 
inferences made on the basis of limited information remain a limitation of the 
findings. While the depth that the analysis could reach in terms of making confident 
conclusions about the intentions of the participants was limited, the high volume of 
responders meant that a breadth of reasons was collected and that patterns could be 
observed. This increased the likelihood that the range of reasons for insulin omission 
found in this study could be considered to be representative of the adult type 1 
diabetes UK population.  
A third limitation of the study was the potential for bias in the method of 
recruitment. Given that the majority of participants were recruited through diabetes 
websites and diabetes support groups on social media, it is possible that only those 
actively seeking support would access and participate in the study. Research has 
shown that online diabetes support groups are typically used to request disease 
specific guidance, to share diabetes management strategies, and to receive emotional 
support (Greene, Choudhry, Kilabuk, & Shrank, 2011). It is therefore possible that 
these groups selectively attract those who identify with having diabetes, and who 
take an active approach to seeking support, when compared to the general population 
of people with type 1 diabetes. This may also be the case for the smaller number of 
participants who were recruited from an NHS clinic. Consequently, those who were 
using social media related to diabetes, and were not attending appointments at the 
diabetes clinic used for recruitment, were not represented in this study. This may 
have meant sampling was potentially biased towards those inclined to better manage 
their diabetes by seeking support and attending appointments. 
Furthermore, the online design meant that only those who were able to use a 
computer, mobile phone, or tablet to complete the questionnaire were included.  
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The use of open-ended questions had the potential to offer difficulties to the less 
literate, or those less able to explain themselves, when compared to closed questions.  
Women were over represented in the sample (77.9%) compared to men 
(22.1%), when compared to other large scale studies, for example Trief et al. (2014) 
reported that in an American sample of 6172 participants, 55% were women. This 
may be a reflection of the over-representation of women in online support groups. 
Krizek, Roberts, Ragan, Ferrara, and Lord, (1999) found that women were 2.5 times 
more likely than men to join a support group, although a review by Mo, Malik, and 
Coulson (2009) suggests that this evidence is mixed. The under-representation of 
men in this sample means that the extent to which the results of the study can be 
generalised is limited.  
An additional limitation of the research was its reliance on self-report 
information. Medical indicators of adherence or omission were not collected from 
participants as this was beyond the scope of the current study, meaning that there 
was the potential for under or over reporting. It is possible therefore that the results 
may be biased, given the tendency for under-reporting of non-adherence in medical 
participants (Stirratt et al., 2015). However, evidence suggests that despite some 
under-reporting, self-reported adherence has a moderate effect size when compared 
to other adherence measures, and can significantly predict clinical outcomes (Stirratt 
et al., 2015; Garber et al., 2004). Further, it was hoped that some of the barriers to 
accurate reporting were addressed by the anonymous response design via computer, 
which minimized issues of confidentiality, and of impression management (Lucas, et 
al., 2014; Singer et al., 1993). 
Further, the way that the question about insulin omission and insulin under 
dosing was interpreted by some participants meant that omission or under dosing 
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were reported as positive behaviours, forming the theme of ‘adaptive responses to 
managing blood sugar levels’. However, the study was designed to look at omission 
only as a negative behaviour (e.g. associated with depression), given that this is the 
prevailing perception in the literature.   
6.6 Theoretical Implications 
The results of this study demonstrate an association between lower self-
efficacy (general and diabetes specific) and insulin omission. While the cross 
sectional correlational design cannot infer causality in this relationship, this finding 
may support a theory of self-efficacy which includes avoidance, drawing on the 
social learning theory concept that individuals perform activities that they can cope 
with and avoid activities which they cannot cope with (Bandura, 1977). The 
relationship between self-efficacy and avoidance has been examined in other areas, 
for example Rodriguez et al., (2016) found that students who had lower self-efficacy 
also had greater academic work avoidance. With diabetes, it may be that low self-
efficacy takes the form of an avoidance of taking insulin doses, resulting in insulin 
omission. While the questionnaires scores are able to assess this relationship, they 
are not able to explain it. The narrative responses reported by participants in this 
study provide personal accounts which may offer some explanation as to how self-
efficacy and insulin omission are related. A theme generated from the narrative 
responses for insulin omission described participants’ avoidance and fear of the 
physical effects of taking their medication may, in part, provide an explanation of 
this. Participants described feeling unable to cope with low blood sugar, for example 
at night, or while driving. This feeling of not being able to cope may be related to 
low self-efficacy. Participants explain or infer that as a result of this, they 
subsequently omit insulin.  
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Much of the existing research investigating insulin omission has looked at 
this behavior particularly in relation to weight control and eating disorders (e.g. 
Polonsky et al., 1994, Crow et al., 1998, Daneman, 2002). The current study 
supports evidence for this, with weight control being the third most commonly 
reported reason for insulin omission. However, this study also demonstrates in a 
large sample a range of associations with and narrative accounts for why people omit 
insulin, aside from weight. This study adds to the small but expanding evidence base 
about the potential multitude of factors that might cause a person to omit their 
insulin medication, despite the potentially harmful health consequences of this.  
Evidence of insulin omission in men has rarely been reported in the literature, 
and in larger studies this has not been reported independently from women (e.g. 
Trief et al., 2014, Farsaei et al., 2014). In the current empirical study, one in three 
women, and just less than one in four men reported omitting insulin, with 2 (10%) of 
the men in this study who restricted insulin reporting doing so to achieve weight 
control. Evidence of men using insulin omission or restriction for weight loss has 
only been reported in one study to the author’s knowledge (Herpertz et al., 1998). 
The findings of the current study should challenge any assumption that insulin 
omission, and insulin omission or restriction for the purpose of weight control, is 
confined to women.  
From the narrative responses obtained in this study it was evident that a 
number of participants reported omitting or restricting insulin for adaptive reasons in 
order to safely and appropriately manage their blood sugar levels. It follows that the 
measurement tool, and by implication other similar measurement tools on which this 
tool was based, may not have separated unsafe from safe responses to insulin and 
this is an area for further development for the current measure. 
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6.7 Clinical Implications 
The consistency of the reported associations between general self-efficacy, 
diabetes specific self-efficacy, insulin omission, and diabetes self-management 
demonstrate that lower self-efficacy is associated with insulin omission and worse 
diabetes self-management.  
For patients’ presenting with insulin omission, interventions that have been 
shown to improve self-efficacy (e.g. Snoek et al, 2008), may be beneficial and 
should be considered by healthcare providers. Similarly, the link between insulin 
omission and low mood, supported by previous research, indicates that interventions 
for depression may be helpful for those presenting with insulin omission and could 
be considered if indicated (Safren et al., 2013).   
Narrative responses from participants indicating what helps them to take their 
insulin as they should, and what would motivate them to do this included the 
achievement of better results, being motivated to prevent complications, more 
support and acceptance from others, more monitoring, lifestyle factors, mood, 
weight, and confidence. There is the potential for these responses to be adapted to 
inform interventions and healthcare in clinical practice. For example, some 
participants state that they want perfect results in terms of their blood sugar control, 
for example a ‘guarantee’ of not experiencing low blood sugar in order to motivate 
them to take their insulin as they should, which may be unrealistic given the many 
factors that can influence blood glucose levels. A ‘black and white’ response, such as 
control being either perfect or bad, may lead to patients becoming unmotivated by 
the lack of perfect results and subsequently becoming less adherent. It is possible 
that interventions such as cognitive behavioural therapy (CBT; Beck, 1979) may be 
beneficial in challenging unhelpful expectations with regards to the management of 
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blood sugar, and may help patients to accept some level of uncertainty and 
fluctuation.  
CBT for adherence and depression has been trialed by Safren et al. (2013) in 
patients with type 2 diabetes. They found that after four months of CBT which 
focused on motivational interviewing, increasing pleasurable activities, thought 
challenging, problem solving, and relaxing, adherence to oral medication improved 
and depression scores reduced. The themes generated as reasons for insulin omission 
by the current study provide potential areas that interventions such as CBT could 
consider. In particular, improving patients’ self-efficacy in managing injections and 
episodes of hypoglycemia in order to reduce fear based avoidance of insulin doses, 
consideration of weight management and eating disorder psychopathology in order 
to support people not to use insulin omission as a weight control strategy, and 
attention to the appraisals that people have of their diabetes and their blood sugar 
control in order to reduce diabetes related emotional distress.  
Further, a number of participants in this study reported that more monitoring 
would be helpful for them, which may be able to be negotiated with diabetes teams 
for those patients for whom insulin omission is a problem. Interventions such as text 
reminders or alerts, glucose monitoring equipment, or more frequent appointments 
might be helpful in these cases. Given that knowledge of the long-term effects of 
insulin omission was a motivator to take insulin appropriately by many, it is possible 
that additional education about this may be helpful when indicated. 
 Importantly, the variety of reasons reported as motivators to take insulin 
offered by participants in this study demonstrates that patients often have ideas about 
what might be helpful for them, and that many of these may be able to be provided 
or outsourced by diabetes teams. Using the knowledge of both patient and 
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professionals collaboratively may facilitate better outcomes in patients (Lin & 
Ciechanowsk, 2008).  
‘Almost half of participants in this study reported that they would not, or do 
not, tell their diabetes team about insulin omission. One explanation for this non-
disclosure is the potential shame or stigma associated with poor diabetes 
management. Shabon (2015) discusses stigma and shame in diabetes in the context 
of poor diabetes management eliciting negative thoughts in people with diabetes, 
such as about not being ‘good enough’, or having ‘failed’, and the fear being judged 
or blamed by professionals for this. This is also discussed by Archer (2014), and 
suggestions made for professionals dealing with shame in diabetes including an 
awareness of non-verbal cues, and training to deliver emotional and psychological 
support.  The results of this study should provide insight into the extent of this 
potential underreporting of insulin omission, and encourage clinicians to consider 
ways to support their patients in being able to share this information. The 
questionnaire developed by this research project or an adapted screening form of this 
measure may provide one way of directly assessing insulin omission in clinical 
practice.’ 
6.8 Future Work 
With regards to the relationship between insulin omission and depression, 
establishing the nature and direction of this relationship is beyond the scope of the 
current study, for example it cannot say whether those that report high levels of 
depression find it more difficult to manage their diabetes and take insulin, or whether 
the side effects of not taking insulin appropriately put patients at risk of low mood. 
Future studies could use a longitudinal design in order to better understand the 
direction of the relationship between mood and insulin omission.  
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Future work might also investigate whether the relationships demonstrated in 
this predominantly UK, type 1 diabetes, adult population between insulin omission 
and self-efficacy, are similar in those with type 2 diabetes, those under the age of 18, 
and beyond the UK. This would provide information about the generalisability the 
relationship between self-efficacy and insulin omission, and might indicate whether 
developing standardized interventions to improve self-efficacy in those who omit 
insulin would be appropriate across these groups.  
The measure developed in this study may, following further work, be 
modified for use in clinical practice. Potential considerations for modification are 
recommended following the results of the study, and feedback from participants 
about the measure. Firstly, a number of participants reported safely and appropriately 
omitting or restricting insulin, and were captured in the ‘insulin omission’ or ‘insulin 
restriction’ group, which aimed to identify use of insulin medication which could 
negatively impact health. This was also identified by a participant in the feedback 
who suggested that the wording was ‘a bit confusing’. Future work could look at 
refining the questions used in order that those who safely and appropriately manage 
their blood sugar through not taking, or restricting their insulin, are easily 
distinguishable and separated.  Second, as suggested by four participants, other areas 
of insulin adherence could be added. For example, the timing of insulin doses is not 
mentioned in this study, but mistimed doses can also cause high blood sugar and 
subsequently be damaging to patients (Brod, Rana & Barnett, 2012). Third, it may be 
helpful to adapt the themes generated from open-ended questions into closed 
question responses to provide a quantitative assessment of attitudes and behaviours 
reported in the narrative responses. Using patient data to shorten the questionnaire to 
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a screening measure for clinicians to use may provide a time efficient way of 
collecting information in clinical practice.  
Ideally future work will establish agreement on the definition and 
measurement of insulin omission, and of insulin adherence in general. The related 
area of under-dosing also merits further investigation.  Additionally, the commonly 
reported area of “forgetting” and the psychological processes associated with this are 
little understood and therefore further research may be helpful. Future research may 
also consider interventions to target insulin omission and under dosing (where both 
are a maladaptive response), and work towards ultimately improving the health and 
wellbeing of those for whom this is a problem.    
6.9 Conclusion 
 The current research reviewed existing measures of insulin adherence 
in type 1 diabetes, and developed a measure of insulin omission. The results of the 
empirical study showed that approximately one third of participants reported insulin 
omission, and that this was related to both lower self-efficacy and higher depression 
scores. Reasons for insulin omission reported by participants in this study could 
usefully be considered to fall under a number of common themes including a) 
Prioritising: Forgetting and the demands of daily lifestyle, b) Diabetes related 
emotional distress, c) Weight control, d) Avoidance: Fear of physical effects, and e) 
Adaptive responses to managing blood sugar levels. 
The questionnaire developed in this study could, with adaption, be used in 
clinical practice as an assessment tool, facilitating communication about insulin 
omission between patients and clinicians. It is hoped that this will promote openness 
and better understanding between patients and clinicians, allowing them to 
collaboratively work together to decrease insulin omission.  
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If successful, a reduction in insulin omission has the potential to help to not 
only reduce the risk of complications, but potentially to improve the longevity and 
quality of life in patients with type 1 diabetes.  
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6. MANUSCRIPT FORMAT AND STYLE 
Articles must be in clear and understandable English. Non-native 
English authors are encouraged to seek the assistance of an 
English-proficient colleague, or a communications agency, such 
as American Journal Experts, to help improve the clarity and 
readability of a paper before it is submitted to the journal. 
For specific information on the parameters and limits for various 
manuscript categories (e.g., section headings, word limits, etc.), 
see Section 5, Manuscript Categories. 
 
6.1. Title Page. All submissions, regardless of article type, require 
a title page. The title page should include the following: full title; a 
short running title (less than 47 characters and spaces combined); 
the first name, middle initial, last name, and highest academic 
degree of each author; each author's affiliation (in English) during 
the time the study was conducted; contact information of the 
corresponding author (name, current address, telephone number, 
fax number, and e-mail address); and the word count and number 
of tables and figures. 
If two authors have equal authorship, it may be noted by * under 
the author list. 
 
6.2. Main Document. The main document file includes the title 
page, abstract, main text, acknowledgements, figure legends, 
references, and tables, in that order. Please do not use headers, 
footers, or endnotes in your paper. 
The Main Document should be in Word document format (not as 
a PDF). This will allow our Editorial Office to verify word count and 
our production staff to convert your paper (if accepted) into an 
article. 
 
6.3. Text Composition. Articles should be written in clear, concise 
English following the recommendations for scientific writing found 
in Scientific Style and Format, the Council of Science Editors 
(CSE) style manual (7th ed., 2006, Reston, VA, Council of 
Science Editors). All accepted manuscripts will be edited 
according to the CSE style manual and The Chicago Manual of 
Style (16th ed., 2010, Chicago, IL, The University of Chicago 
Press) by ADA professional publications staff. The authors are 
responsible for all statements made in their articles or editorials, 
including any editing changes made by staff. Proof pages will be 
sent to the corresponding author and should be read carefully. 
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The designations type 1 diabetes and type 2 diabetes should be 
used when referring to the two major forms of diabetes. 
Abbreviations for diabetes, such as T2D for type 2 diabetes, 
should not be used. The term diabetic should not be used as a 
noun. 
All manuscripts should be double-spaced, in Arial or Times New 
Roman 12-point font, and saved as a .doc, .txt, or .rtf file. In 
addition, please do not "lock" or "page protect" your document, 
and avoid using footnote and endnote functions. 
 
6.4. Abbreviations and Units. Abbreviations should be used only 
when necessary, e.g., for long chemical names (HEPES), 
procedures (ELISA), or terms used throughout the article. See 
the list of abbreviations that need not be defined; all others must 
be defined at first use. Abbreviate units of measure only when 
used with numbers. Abbreviations may be used in tables and 
figures. The CSE style manual contains lists of standard scientific 
abbreviations. 
Clinical laboratory values and units should be in Système 
International (SI) form. Kilocalories should be used rather than 
kilojoules.  
HbA1c values should be dually reported as “% (mmol/mol).” 
Please use the NGSP’s HbA1c converter 
at http://www.ngsp.org/convert1.asp to calculate HbA1c values as 
both % and mmol/mol. 
6.5. Font. Text, including title and author names, should be in 12-
point Arial or Times New Roman. Please avoid using boldface 
font. Text in tables should be no smaller than 10-point font. 
 
6.6. Margins. Margins should be 1" at the top and bottom and 1" 
on the left and right sides. 
 
6.7. Acknowledgments. The acknowledgments are located after 
the main text and before the reference list. Acknowledgments 
should contain the author contributions paragraph, brief 
statements of assistance, the guarantor's name (person[s] taking 
responsibility for the contents of the article), funding/financial 
support, conflict of interest statement, and reference to prior 
publication of the study in abstract form, where applicable. 
 
6.8. References. Please place the reference list after the main 
text and acknowledgments (if applicable). Original Articles are 
limited to 40 references. Letters are allowed 5 references. Review 
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Articles are allowed 60 references, and meta-analyses should 
have no more than 40 references. 
 
Reference numbers in the text should appear in chronological 
order in normal type and in parentheses [e.g., “In the study by 
Norton et al. (23)...”]. Please do not use the footnote or endnote 
function to cite studies or create a reference list. A reference 
manager must have the ability to customize the display of 
references. For example, the reference application should have 
the option to list the references at the end of the paper, as 
opposed to listing the references as endnotes or footnotes at the 
bottom of each page, and should not embed the list in the text as 
a series of endnotes/footnotes. When using a reference manager 
(e.g., Thomson's EndNote Reference Program), don't forget to 
generate the list as a bibliography in a style suitable to Diabetes 
Care, and then save and submit as the final step to creating the 
references. Otherwise, references should be manually inserted. 
All authors must be listed by first initials and last name in each 
reference, and please provide inclusive page numbers. Journal 
titles should be abbreviated according to the National Library of 
Medicine’s List of Journals Indexed for Medline; for unlisted 
journals, please provide complete journal titles. Material in press 
may be cited, but copies of such material may be requested. 
Authors are responsible for the accuracy of the references. 
Click here for examples of how references should be formatted. 
 
6.9. Supplemental Material. Non-essential tables, figures, and/or 
videos may accompany articles as online-only supplemental 
material files, but authors are asked to include a comment to the 
editor at the time of manuscript submission that explains the 
rationale and justification for submitting and possibly posting the 
supplemental information. 
All online-only supplemental material files should be combined in 
one document file whenever possible and uploaded during the 
submission process. The file must be clearly labeled as “Online-
Only Supplemental Material." In addition, supplemental 
material online-only files must be referenced in the main text of 
the manuscript at least once (e.g., “Supplemental Table S1”). 
All online-only supplemental material files are subject to peer 
review but will not  be composed, copyedited, or proofread by 
production staff. As such, authors are encouraged to review 
supplemental material files carefully before submission. 
Lists that include names of principal investigators or writing 
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groups may appear in print or as online-only supplemental 
material. Lists of names exceeding 150 words should be 
submitted as online-only supplemental material. Names of 
principal investigators or writing groups should otherwise be 
included in an in-text appendix, located at the end of the main 
document before the references. 
 
Supplemental material containing very large datasets should be 
cited in the text with a URL to the material hosted on an author-
affiliated website or may appear with a note that the data is 
available upon request to the author. 
 
6.10. Tables. Each table should be inserted on a separate page at 
the end of the document with the table number, title, and legend 
indicated. Table legends should be inserted below the table and 
should not be included inside the table. Tables should be created 
using Word and the "Insert Table" command. Please use Arial or 
Times New Roman font, no smaller than 10-point. Tables with 
internal divisions are not allowed (Tables 1A and B) and should 
be submitted as individual tables (Tables 1 and 2). Please avoid 
using shading within a table. If a table includes data that require 
explanation in the legend, apply the following sequence of 
symbols, from top to bottom, left to right: *, †, ‡, §, ||, ¶, #, **, ††, 
‡‡. 
 
6.11. Figures. Diabetes Care uses digital publishing methods 
throughout the journal production process. If your article is 
accepted, it will be published in both the print and online journal. 
The following sections provide information on how to format your 
figures to ensure the best possible reproduction of your images. 
Size. Figures should be produced at the size they are to appear in 
the printed journal. Please make sure your figures will fit in one, 
two, or three columns in width. Multi-paneled figures should be 
assembled in a layout that leaves the least amount of blank 
space. 
1 column = 13 picas wide, 2.2 in, 5.6 cm 
2 columns = 28 picas wide, 4.6 in, 11.7 cm 
3 columns = 41 picas, 6.8 in, 17.3 cm 
Font. At 100% size, fonts should be 8-10 points and used 
consistently throughout all figures. 
Text. Information on the axes should be succinct, using 
abbreviations where possible, and the label on the y-axis should 
read vertically, not horizontally. Key information should be placed 
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in any available white space within the figure; if space is not 
available, the information should be placed in the legend. In 
general, figures with multiple parts should be marked A, B, C, 
etc., with a description of each panel included in the legend rather 
than on the figure. 
 
Line and bar graphs. Lines in graphs should be bold enough to be 
easily read after reduction, as should all symbols used in the 
figure. Data points are best marked with the following symbols, 
again assuring that they will be readily distinguishable after 
reduction: . In the figure legend, please use 
words rather than the symbols; e.g., "black circles = group 1; 
white squares = group 2; black bars = blood glucose; white bars = 
C-peptide." Bars should be black or white only, unless more than 
two datasets are being presented; additional bars should be 
drawn with clear bold hatch marks or stripes, not shades of gray. 
Line or bar graphs and flow charts should be created in black and 
white (if more than two datasets, multiple bars can be drawn with 
clear, bold hatch marks or stripes) or color (see color printing 
fees), not shades of gray, which are difficult to reproduce in even 
tones. 
 
Formatting digital figures files for print and online reproduction. To 
meet ADA’s quality standards for publication, it is important to 
submit digital art that conforms to the appropriate resolution, size, 
color mode, and file format. Doing so will help to avoid delays in 
publication and maximize the quality of images, both online and in 
print. Please refer to ADA's Digital Art Guidelines when preparing 
your files. If you are unable to provide files that meet the 
specifications outlined in the Guidelines, you may submit your 
original source files (files from the program in which they were 
originally created). 
Reproductions. If materials (e.g., figures and/or tables) are taken 
from other sources, the author must provide written permission for 
reproduction from the original publisher and author at the time of 
submission. In addition, the source should be cited at the end of 
the figure legend. For more information, refer to Permissions: 
Help for Authors. 
 
Referencing style guide 
 
 Journal articles:  
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Banting FG, Best C. The internal secretion of the pancreas. J Lab Clin Med 
1922;7:251-266  
 
Abstracts:  
Seaborn J. Gastrointestinal side-effects of high-fiber diets in diabetic rats (Abstract). 
Gut 1992;33:A4304  
 
Books:  
Allen FM. Studies Concerning Glycosuria and Diabetes. Bradley RF, Krall LP, Eds. 
Cambridge, MA, Harvard Univ. Press, 1913  
 
Chapters in books:  
Stauffacher W, Renold AK. Pathophysiology of diabetes mellitus. In Joslin's 
Diabetes Mellitus. 11th ed. Marble A, White P, Bradley RF, Krall LP, Eds. 
Philadelphia, Lea & Febiger, 1971, p. 35-98  
 
Government publications:  
Fajans SS (Ed.). Diabetes Mellitus. Washington, DC, U.S. Govt. Printing Office, 
1976 (DHEW publ. no. NIH 76-854)  
 
Proceedings and symposia:  
Steel JM. Prepregnancy counseling and the management of the pregnant woman 
with diabetes. In Proceedings of the 39th Annual Advanced Postgraduate Course, 
Orlando, FL, 1992. Alexandria, VA, American Diabetes Association, p. 97–98  
 
Online publications:  
Beta cell function in type 2 diabetes: glucose metabolism and insulin secretion in the 
normal pancreas [article online], 1999. Available from 
http://www.amaryl.com/TXT/Clinical_Management/Overview/beta_cell_failure_TX
T.html. Accessed 4 May 2000  
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Appendix F 
 
Participant Information Sheet 
 
Participant information sheet: Phase 1: patient (version: 1.1 date: 27.04.2016) 
 
 
 
 
 
 
 
Participant Information Sheet 
A study of adults with type 1 diabetes: investigating insulin omission 
 
Researcher: Sophie Ames (Trainee Clinical Psychologist) 
Supervised by: Dr Sian Coker 
Doctoral Programme in Clinical Psychology,  
School of Medicine and Health Sciences, 
University of East Anglia 
 
 
 
Invitation and brief summary 
We would like to invite you to take part in a research study conducted by The 
University of East Anglia and Cambridgeshire and Peterborough NHS Foundation 
Trust. The purpose of the study is to understand in depth why some people find 
managing their insulin medication for diabetes difficult. We are making a 
questionnaire to give to people to have diabetes, about insulin, and would like your 
help in creating this.  You could take part by meeting the researcher at one of your 
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local diabetes clinics, or you could take part over email. Before you decide if you 
would like to take part, we will tell you why the research is being done and what it 
will involve for you. You will then be able to decide if you are interested in taking 
part in the study. Please get in touch if anything is not clear to you or you would like 
more information.  
 
What is the purpose of the study? 
The overall purpose of the study is to understand in depth some of the reasons that 
people find managing their insulin medication difficult. This will involve developing 
a questionnaire that will ask questions about insulin in patients with type 1 diabetes. 
The research is being conducted as part of a Doctorate in Clinical Psychology at the 
University of East Anglia. This kind of research can help services understand some 
of the needs of people with diabetes, and to develop interventions to help. 
 
Why have I been asked to take part? 
We are interested in the views of people with experience of type 1 diabetes. This 
could be people that have type 1 diabetes themselves, or care for someone that does.   
 
What will the study involve? 
After looking through the information and agreeing for the researcher to contact you, 
the researcher will get in touch to ask if you would like to meet in person, or take 
part over email. If in person, this will probably be at your local diabetes clinics. If 
email, the researcher will email you on the address that you provided. You will see a 
copy of a questionnaire about insulin. We are interested in what you think of the 
questions, and any suggestions for different questions, wording, or format. There are 
no right or wrong answers, and you are free to decline to comment on anything that 
you do not wish to. It will take no more than 30 minutes. 
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Will my information be kept confidential? 
 
All personal information will be kept confidential. The data from the discussion will 
be kept securely at The University of East Anglia. It will be destroyed 10 years after 
the research has finished. You do not need to share any sensitive information. You 
will be given information about where to access support for diabetes. You will be 
given information about where to access support about issues relating to managing 
diabetes.  
 
 
What are the possible disadvantages / benefits of taking part? 
It is possible that the topics of difficulties with managing diabetes will be upsetting 
for some people. An information sheet will be provided with where you can access 
support. There will be no direct benefits to you for taking part in this study. 
However, your contributions will provide the researcher with valuable feedback to 
develop the questionnaire. This information is likely to improve the questionnaire, 
which may help improve the care of people with diabetes in the future. 
 
What if there is a problem? 
A list of contact details for services and organisations who may be able to support 
you will be provided in case the questions raise any issues that you would like to 
discuss further. You will also be able to contact myself or my research supervisor if 
you have any concerns about the study (details below). You are free to stop 
commenting on the questionnaire or withdraw at any point, without giving a reason, 
until you have sent the replies back by email.  
 
What will happen to the results of the research study? 
The results of this study may be published in scientific journals and at medical and 
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psychological academic conferences.  You will not be identified in any report or 
publication.  
 
Who has reviewed the study? 
This study has been checked by the University of East Anglia and the South-West 
Cornwall and Plymouth Research Ethics Committee to protect your safety, rights, 
well-being and dignity.  
 
Any further queries? 
If you have a concern or complaint about any aspect of the study, you may contact 
me in the first instance. Alternatively, you could contact my research supervisor, Dr. 
Sian Coker (see contact details below) If you remain unhappy and wish to complain 
formally, you can contact Professor Ken Laidlaw, (Director of UEA Clinical 
Psychology Course, 01603 593076)  
 
Contact Details: 
Sophie Ames 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
s.ames@uea.ac.uk 
 
Dr. Sian Coker 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
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Appendix G 
 
Participant information sheet 
 
Participant information sheet: Phase 1: Clinicians (version 1.1 15.05.2016) 
 
 
 
 
 
 
 
Participant Information Sheet 
A study of adults with type 1 diabetes: investigating insulin omission 
 
Researcher: Sophie Ames (Trainee Clinical Psychologist) 
Supervised by: Dr Sian Coker 
Doctoral Programme in Clinical Psychology,  
School of Medicine and Health Sciences, 
University of East Anglia 
 
 
 
Invitation and brief summary 
We would like to invite you to take part in a research study conducted by The 
University of East Anglia and Cambridgeshire and Peterborough NHS Foundation 
Trust. The study is investigating how often, when, and why patients with type 1 
diabetes do not take insulin that they need. It will involve meeting with the 
researcher to discuss a questionnaire that is being developed.  Before you decide if 
  185
you would like to take part, we will tell you why the research is being done and what 
it will involve for you. You will then be able to decide if you are interested in taking 
part in the study. Please get in touch if anything is not clear to you or you would like 
more information.  
 
What is the purpose of the study? 
The overall purpose of the study is to understand in depth some of the reasons that 
people find managing their insulin medication difficult. This will involve developing 
a questionnaire that will be able to detect, measure, and identify some of the reasons 
for insulin omission in patients with type 1 diabetes. The research is being conducted 
as part of a Doctorate in Clinical Psychology at the University of East Anglia. This 
kind of research can help services understand some of the difficulties and needs of 
people with diabetes, and to develop interventions so that these needs can be met.  
 
Why have I been asked to take part? 
We are interested in the views of clinicians who work with people with type 1 
diabetes to help us to develop the questionnaire.   
 
What will the study involve? 
The study will involve you attending a small discussion with the researcher and other 
clinicians, or meeting with the researcher individually, depending on availability. 
The questionnaire as it stands will be presented, and you will be asked for your 
opinion on the range, form and content of the questions. There are no right or wrong 
answers, and you are free to decline to answer any question you do not feel happy 
with. The group will last a maximum of one hour, and will be held on NHS premises 
in or around Norwich.  
 
  186
Will my information be kept confidential? 
 
The data from the discussion will be kept securely at The University of East Anglia. 
It will be destroyed 10 years after the research has finished. Personal disclosures of a 
sensitive nature will not be necessary. You will be given information about where to 
access support about issues relating to managing diabetes.  
 
What are the possible disadvantages / benefits of taking part? 
It is possible that the topics discussed such as patients engaging in behaviour which 
puts them at risk will be distressing. An information sheet will be provided with 
where you can access support. There will be no direct benefits to you for taking part 
in this study. However, your contributions will provide the researcher with more 
valuable feedback to develop the questionnaire. This information is likely to improve 
the questionnaire, which may help improve the care of people with diabetes in the 
future. 
 
What if there is a problem? 
A list of contact details for services and organisations who may be able to support 
you will be provided in case the questions raise any issues that you would like to 
discuss further. You will also be able to contact myself or my research supervisor if 
you have any concerns about the study (details below). You are free to leave the 
discussion at any point.   
 
What will happen to the results of the research study? 
The results of this study may be published in scientific journals and at conferences.  
You will not be identified in any report.  
 
Who has reviewed the study? 
This study has been checked by the University of East Anglia and the South-West 
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Cornwall and Plymouth Research Ethics Committee to protect your safety, rights, 
well-being and dignity.  
 
Any further queries? 
If you have a concern or complaint about any aspect of the study, you may contact 
me in the first instance. Alternatively, you could contact my research supervisor, Dr. 
Sian Coker (see contact details below) If you remain unhappy and wish to complain 
formally, you can contact Professor Ken Laidlaw, (Director of UEA Clinical 
Psychology Course, 01603 593076)  
 
Contact Details: 
Sophie Ames 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
s.ames@uea.ac.uk 
 
Dr. Sian Coker 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
 
 
 
 
 
  188
Appendix H 
 
Participant Information Sheet 
 
 
Participant information sheet: Phase 2 (version 2.1, date 27.04.2016) 
 
 
 
 
 
 
 
Participant Information Sheet 
A study of  adults with type 1 diabetes: investigating insulin omission 
 
Researcher: Sophie Ames (Trainee Clinical Psychologist) 
Supervised by: Dr Sian Coker 
Doctoral Programme in Clinical Psychology,  
School of Medicine and Health Sciences, 
University of East Anglia 
 
 
 
Invitation and brief summary 
We would like to invite you to take part in a research study conducted by The 
University of East Anglia and Cambridgeshire and Peterborough NHS Foundation 
Trust. The study will investigate people’s experiences of managing their type 1 
diabetes. Before you decide if you would like to take part, we will tell you why the 
research is being done and what it will involve for you. You will then be able to 
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decide if you are interested in taking part in the study. If you would like more time to 
think about it, you can come back to this web page at a later date. Please get in touch 
if anything is not clear to you or you would like more information.  
 
What is the purpose of the study? 
The purpose of the study is to understand in depth some of the reasons that people 
find managing their insulin medication difficult. The research is being conducted as 
part of a Doctorate in Clinical Psychology at the University of East Anglia. This kind 
of research can help services understand some of the difficulties and needs of people 
with diabetes, and to develop interventions so that these needs can be met.  
 
Why have I been asked to take part? 
We are interested in the views of adults between 18-65 who have had type 1 diabetes 
for over 1 year, and live within the European Union (EU).  
 
What will the study involve? 
The study will involve you completing a series of questionnaires online which can be 
done at home. The questionnaires have all been approved by an ethics committee. 
You will be asked about the things that you do to manage your diabetes, some 
questions about insulin, your experiences, your mood, and how able you feel to 
manage these things. Some of the questions will have space for you to write about 
these things in detail. The questionnaires should take around 30 minutes to complete. 
There are no right or wrong answers, and you are free to decline to answer any 
question you do not feel happy with.  
 
Will my information be kept confidential? 
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All personal information will be kept confidential. Parts of your responses may be 
quoted in reports of the research, but all identifying details will be removed. We will 
not ask for your name or for any contact details. Your GP and any other health 
professionals will not be informed that you are taking part in the study. It will not be 
possible for the researchers to contact them. The data from the questionnaires will be 
kept securely at The University of East Anglia. It will be destroyed 10 years after the 
research has finished. You are able to withdraw at any point up until you complete 
the survey without giving a reason.  
 
What are the possible disadvantages / benefits of taking part? 
You will be asked to complete a series of questionnaires which can be done at home. 
It is possible that the topics discussed such as mood and any difficulties with 
managing your diabetes will be difficult for some people. An information sheet will 
be provided with where you can access support. There will be no direct benefits to 
you for taking part in this study. However, the answers that you give will provide the 
researchers with more information about diabetes self-management. This 
information may help improve the care of people with diabetes in the future. 
 
What if there is a problem? 
A list of contact details for services and organisations who may be able to support 
you will be provided in case the questions raise any issues that you would like to 
discuss further. You will also be able to contact myself or my research supervisor if 
you have any concerns about the study (details below). You are free to stop 
completing the survey at any point.  
 
What will happen to the results of the research study? 
The results of this study may be published in scientific journals and at medical and 
psychological academic conferences.  You will not be identified in any report or 
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publication.  
 
Who has reviewed the study? 
This study has been checked by the University of East Anglia and the South-West 
Cornwall and Plymouth Research Ethics Committee to protect your safety, rights, 
well-being and dignity.  
 
Any further queries? 
If you have a concern or complaint about any aspect of the study, you may contact 
me in the first instance. Alternatively, you could contact my research supervisor, Dr. 
Sian Coker (see contact details below) If you remain unhappy and wish to complain 
formally, you can contact Professor Ken Laidlaw, (Director of UEA Clinical 
Psychology Course, 01603 593076)  
 
Contact Details: 
Sophie Ames 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
s.ames@uea.ac.uk 
 
Dr. Sian Coker 
Doctoral Programme in Clinical Psychology, 
Department of Psychological Sciences 
Norwich Medical School 
University of East Anglia 
Norwich Research Park 
NORWICH 
NR4 7TJ 
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Appendix I 
 
Final Page of Survey 
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Appendix J 
 
Insulin Questionnaire Version 1 
 
 
Insulin Questionnaire – unvalidated version 1 23.02.2016 
 
 
1a) Do you ever skip (miss out) insulin doses that you know you should take?  
 
 
 
 
If yes: 
 
1b) On how many of the past 7 days did you skip an insulin dose that you knew you 
should take?  
….   days 
 
1c) How many times in the past 7 days did you skip an insulin does that you knew 
you should take?  
…. times  
 
1d) On how many days in the past month (28 days) did you skip an insulin dose that 
you knew you should take?  
…. Days 
 
1e) How many times in the past month days did you skip an insulin dose that you 
knew you should take?   
.... times  
 
1f) Please explain in your own words why you skipped an insulin dose that you 
knew you should take. 
 
 
 
 
 
 
 
2a) Do you ever take less insulin than you know you should take?  
 
 
 
 
If yes:  
 
Please type here….. 
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2b) On how many of the past 7 days did you take less insulin than you knew you 
should take? …. days 
 
2c) How many times in the past 7 days did you take less insulin than you knew you 
should take?  
…. times 
 
2d) On how many days in the last month did you take less insulin than you knew you 
should take?  
….days 
 
2e) How many times in the past month did you take less insulin than you knew you 
should take?  
…. times 
 
2f) Please explain in your own words why you took less insulin than you knew 
you should. 
 
 
 
 
 
 
 
3a) Do you ever forget to take your insulin?  
 
 
 
 
 
If yes: 
 
3b) On how many of the last 7 days did you forget to take your insulin? 
….. days 
 
3c) How many times in the last 7 days did you forget to take your insulin?  
….. times 
 
3d) On how many days in the last month did you forget to take your insulin? 
…. Days 
 
3e) How many times in the last month did you forget to take your insulin? 
….. times  
 
3f) Please explain in your own words why you forgot to take your insulin. 
 
 
 Please type here….. 
Please type here….. 
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4a) Do you ever stop taking your insulin for a while? 
 
4b) Please explain in your own words why you stop taking insulin for a while.  
 
 
 
 
 
 
 
 
5) Does your mood effect how you take insulin? If Yes, how?  
 
 
 
 
 
 
 
6) Under what circumstances are you more likely to take insulin as you should?  
 
 
 
 
 
 
 
 
7) Under what circumstances are you less likely to take insulin as you should?  
 
 
 
 
 
Please type here….. 
Please type here….. 
Please type here….. 
Please type here….. 
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Appendix K 
 
Insulin Questionnaire Version 2 
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Appendix L 
 
Thematic Map:  
 
Reasons for Insulin Omission 
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Appendix M 
Diabetes self management questionnaire 
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Appendix N 
New general self-efficacy questionnaire 
1 1. I will be able to achieve most of the goals that I have set for myself. 
2 2. When facing difficult tasks, I am certain that I will accomplish them. 
3 3. In general, I think that I can obtain outcomes that are important to me. 
4 4. I believe I can succeed at most any endeavor to which I set my mind. 
5 5. I will be able to successfully overcome many challenges. 
6 6. I am confident that I can perform effectively on many different tasks. 
7 7. Compared to other people, I can do most tasks very well. 
8 8. Even when things are tough, I can perform quite well. 
 
Response 
Format 
 1 = Not at all true   2 = Hardly true   3 = Moderately true   4 = 
Exactly true 
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Appendix O  
Diabetes specific self efficacy questionnaire – short form 
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Appendix P 
Patient health questionnaire version 9 (PHQ-9) 
 
 
